WO2025206232A1 - Procédé de traitement de surface pour poudre, poudre traitée en surface par ledit procédé, agent de traitement pour poudre, poudre traitée en surface par ledit agent de traitement et composition cosmétique - Google Patents

Procédé de traitement de surface pour poudre, poudre traitée en surface par ledit procédé, agent de traitement pour poudre, poudre traitée en surface par ledit agent de traitement et composition cosmétique

Info

Publication number
WO2025206232A1
WO2025206232A1 PCT/JP2025/012601 JP2025012601W WO2025206232A1 WO 2025206232 A1 WO2025206232 A1 WO 2025206232A1 JP 2025012601 W JP2025012601 W JP 2025012601W WO 2025206232 A1 WO2025206232 A1 WO 2025206232A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mass
acid
powder
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/012601
Other languages
English (en)
Japanese (ja)
Inventor
奈々 原矢
天音 本間
左枝 大岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of WO2025206232A1 publication Critical patent/WO2025206232A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara

Definitions

  • the present invention relates to a powder treatment agent with excellent storage stability.
  • Powders used in cosmetics are subjected to various surface treatments to improve usability (smoothness when applied to the skin, spreadability, moisturizing feeling, non-greasy feeling, adhesion, etc.), cosmetic effect (coverage, soft focus, light absorption/dispersion, color development, etc.), cosmetic durability (prevention of makeup dulling or discoloration caused by the powder becoming wet with sweat or sebum, adhesion, resistance to removal and creasing, etc.), formulation stability (dispersibility, emulsion stability), and moldability. Since the desired effects vary depending on the application, numerous surface treatment agents have been proposed. One example is the long-standing attempt to treat the surface of powders with N-acylamino acids.
  • Patent Document 1 describes orienting and adsorbing the N-acylamino acid in water or an aqueous solvent using metal ions with a positive charge of two or more to bond negatively charged hydroxyl groups on the powder surface with negatively charged carboxyl groups on the N-acylamino acid.
  • This method requires the steps of filtration, washing, drying, and pulverization, resulting in limited commercial merit. Furthermore, the drying and pulverization steps can lead to the powder's tendency to aggregate, resulting in insufficient balance between hydrophilicity and hydrophobicity, cosmetic durability, evenness, and antiseptic efficacy. It also places a significant burden on the environment.
  • JP 2014-19783 A there is also a known modification method (JP 2014-19783 A) in which plasma is applied to the powder to be treated before surface treatment, causing an acylamino acid to react directly with the surface.
  • This method requires special equipment, such as electrodes to generate the plasma.
  • the present invention aims to provide a treatment agent that can be used to surface treat powders using a simple method that requires minimal man-hours and no special equipment, and that has excellent storage stability.
  • a method for surface treatment of powder comprising: (i) a step of treating powder with a treatment liquid A; and (ii) a step of treating powder with a treatment liquid B,
  • Treatment solution A contains (a) one or more compounds selected from N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof, (b) one or more compounds selected from fatty acids having a carbon chain length of C8 to C22 and salts thereof, (c) a polyhydric alcohol and/or (d) arginine, and (e) water; the concentration of the compound (a) in the treatment liquid A is 5% by mass or more, When the treatment solution A does not contain arginine, the mass ratio of the compound (b) to the compound (a) in the treatment solution A (compound (b)/compound (a)) is 0.13 or less; When the treatment liquid A does not contain a polyhydric alcohol, the mass ratio of the compound (b) to the compound (a) in the treatment liquid A (
  • the metal ions (f) include ions of one or more metals selected from the group consisting of calcium, zinc, and magnesium.
  • the processing solution B is a weakly acidic, neutral or alkaline aqueous solution.
  • the molar ratio of the metal ion (f) in the treatment solution B to the compound (a) in the treatment solution A is 0.3 to 10.
  • the mass ratio of the powder to the treatment liquid A is 0.1 to 10,000.
  • the mass ratio of the powder to the treatment liquid B is 0.5 to 10,000.
  • a powder treatment agent containing treatment liquid A and treatment liquid B contains (a) one or more compounds selected from N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof, (b) one or more compounds selected from fatty acids having a carbon chain length of C8 to C22 and salts thereof, (c) a polyhydric alcohol and/or (d) arginine, and (e) water; the concentration of the compound (a) in the treatment liquid A is 5% by mass or more, When the treatment solution A does not contain arginine, the mass ratio of the compound (b) to the compound (a) in the treatment solution A (compound (b)/compound (a)) is 0.13 or less; When the treatment liquid A does not contain a polyhydric alcohol, the mass ratio of the compound (b) to the compound (a) in the treatment liquid A (compound (b)/compound (a)) is 0.25 or less,
  • the treatment liquid B is (f) an aqueous
  • the metal ions (f) include ions of one or more metals selected from the group consisting of calcium, zinc, and magnesium.
  • treatment solution B is a weakly acidic, neutral or alkaline aqueous solution.
  • the molar ratio of the metal ion (f) in treatment solution B to the compound (a) in treatment solution A is 0.3 to 10.
  • a powder whose surface is coated with a composition comprising: (a) one or more compounds selected from N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof; (b) one or more compounds selected from fatty acids having a carbon chain length of C8 to C22 and salts thereof; (c) a polyhydric alcohol and/or (d) arginine; (e) water; and (f) a metal ion;
  • the mass ratio of compound (b) to compound (a) (compound (b)/compound (a)) is 0.13 or less
  • the mass ratio of the compound (b) to the compound (a) (compound (b)/compound (a)) is 0.25 or less;
  • the powder, wherein the metal ions (f) include ions of alkaline earth metals or ions of zinc.
  • FIG. 1 is a graph showing the synergistic effect of surface treatment compositions A and B in terms of antifungal effect.
  • FIG. 1 is a diagram showing the appearance of the coating films of Example 11', Reference Example 1', and Reference Example 3'.
  • the method for surface treating powder of the present invention comprises the following steps:
  • the method includes (i) a step of treating a powder with a treatment liquid A, and (ii) a step of treating a powder with a treatment liquid B.
  • treatment liquid A contains the following components: (a) one or more compounds selected from N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof; (b) one or more compounds selected from fatty acids having a carbon chain length of C8 to C22 and salts thereof; (c) a polyhydric alcohol and/or (d) arginine; (e) water; and Includes:
  • the treatment solution B contains (f) metal ions.
  • acyl component constituting the N-acyl group of an N-acylamino acid having an acyl group with a carbon chain length of C8 to C22 include acyl groups derived or derivable from linear or branched, saturated or unsaturated fatty acids having 8 to 22 carbon atoms, such as single fatty acid acyl groups such as octanoyl, caproyl, nonanoyl, caprinoyl, decanoyl, undecanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, behenoyl, palmitoleoyl, oleoyl, and linoleoyl, as well as naturally occurring mixed fatty acid acyl groups such as coconut oil fatty acid acyl and hardened beef tallow fatty acid acyl, as well as aromatic carboxylic acid acyl groups such as benzoic acid acyl.
  • acyl group of N-acylamino acids having an acyl group with a carbon chain length of C8 to C20 myristoyl, palmitoyl, stearoyl, behenoyl, palmitoleyl, oleoyl, and linoleoyl are preferred, myristoyl, palmitoyl, and stearoyl are more preferred, and palmitoyl and stearoyl are even more preferred.
  • Salts of N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 include pharmacologically acceptable salts, and examples thereof include alkali metal salts such as lithium salts, sodium salts, and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; basic organic salts; and triethanolamine salts. Of these, from the viewpoint of solubility, sodium salts, potassium salts, ammonium salts, and triethanolamine salts are preferred, sodium salts and potassium salts are more preferred, and sodium salts are even more preferred.
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include myristoyl glutamic acid, the sodium salt of myristoyl glutamic acid, the potassium salt of myristoyl glutamic acid, palmitoyl glutamic acid, the sodium salt of palmitoyl glutamic acid, the potassium salt of palmitoyl glutamic acid, stearoyl glutamic acid, the sodium salt of stearoyl glutamic acid, the potassium salt of stearoyl glutamic acid, oleoyl glutamic acid, the sodium salt of oleoyl glutamic acid, and the potassium salt of oleoyl glutamic acid, and myristoyl glutamic acid, and myristoyl glutamic acid More preferred
  • Preferred N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include myristoyl glutamic acid, sodium myristoyl glutamate, disodium myristoyl glutamate, potassium myristoyl glutamate, dipotassium myristoyl glutamate, palmitoyl glutamic acid, sodium palmitoyl glutamate, disodium palmitoyl glutamate, potassium palmitoyl glutamate, dipotassium palmitoyl glutamate, stearoyl glutamic acid, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearoyl glutamate, dipotassium stearoyl glutamate, sodium oleoyl glutamate, oleoyl glutamic acid, disodium oleoyl glutamate, potassium oleoyl glutamate, and dipotassium oleoyl glutamate, and
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include palmitoyl glutamic acid, sodium palmitoyl glutamate, disodium palmitoyl glutamate, potassium palmitoyl glutamate, dipotassium palmitoyl glutamate, palmitoyl glutamic acid triethanolamine salt, stearoyl glutamic acid, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearoyl glutamate, stearo ...
  • palmitoyl glutamic acid sodium palmitoyl glutamate, disodium palmitoyl glutamate, potassium palmitoyl glutamate, dipotassium palmitoyl glutamate, stearoyl glutamic acid, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearoyl glutamate, or dipotassium stearoyl glutamate may be used.
  • the use of these N-acyl amino acids can improve the balance between hydrophilicity and hydrophobicity of the treated powder, as well as multiple properties selected from among makeup durability, evenness, and antiseptic effect.
  • the concentration of compound (a) in treatment liquid A is 5% by mass or more, and preferably 7% by mass or more.
  • the concentration of compound (a) in treatment liquid A may be preferably 5 to 30% by mass, more preferably 5 to 25% by mass, and even more preferably 7 to 20% by mass.
  • the fatty acid having a carbon chain length of C8 to C22 which is compound (b), may be a straight-chain fatty acid or a branched-chain fatty acid, with straight-chain fatty acids being preferred.
  • the fatty acid having a carbon chain length of C8 to C22 may be a saturated fatty acid or an unsaturated fatty acid, with saturated fatty acids being preferred.
  • the fatty acid having a carbon chain length of C8 to C22 is preferably a fatty acid having a carbon chain length of C8 to C20, more preferably a fatty acid having a carbon chain length of C14 to C18, and even more preferably a fatty acid having a carbon chain length of C16 to C18.
  • fatty acids having a carbon chain length of C8 to C22 include caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, eicosenoic acid, erucic acid, hardened beef tallow fatty acid, coconut oil fatty acid, and palm oil fatty acid.
  • Fatty acids having a carbon chain length of C8 to C22 are preferably lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidic acid, behenic acid, and oleic acid, more preferably myristic acid, palmitic acid, palmitoleic acid, stearic acid, and oleic acid, even more preferably myristic acid, palmitic acid, and stearic acid, and even more preferably palmitic acid and stearic acid.
  • Salts of fatty acids having a carbon chain length of C8 to C22 include pharmacologically acceptable salts, such as alkali metal salts (lithium salt, sodium salt, potassium salt, etc.); alkaline earth metal salts (calcium salt, magnesium salt, etc.); ammonium salts; basic organic salts; triethanolamine salts, etc.
  • alkali metal salts lithium salt, sodium salt, potassium salt, etc.
  • alkaline earth metal salts calcium salt, magnesium salt, etc.
  • ammonium salts basic organic salts
  • triethanolamine salts etc.
  • sodium salts, potassium salts, and ammonium salts are preferred, sodium salts and potassium salts are more preferred, and sodium salts are even more preferred.
  • the fatty acid having a carbon chain length of C8 to C22 as compound (b) preferably has a partition coefficient of 10 or less, more preferably 8.5 or less.
  • the concentration of compound (b) in treatment solution A is preferably 6% by mass or less, and may be 5% by mass or less, 4% by mass or less, 3% by mass or less, 2.6% by mass or less, 2% by mass or less, 1.6% by mass or less, 1.3% by mass or less, 1% by mass or less, 0.7% by mass or less, or 0.5% by mass or less.
  • the concentration of compound (b) in treatment solution A is preferably 8% by mass or less, and may be 7% by mass or less, 6% by mass or less, 5% by mass or less, 4.5% by mass or less, 4% by mass or less, 3.5% by mass or less, 3% by mass or less, 2.5% by mass or less, 2% by mass or less, 1.5% by mass or less, or 1% by mass or less.
  • the concentration of compound (b) in treatment liquid A is preferably 0.02 mass% or more, more preferably 0.04 mass% or more, even more preferably 0.06 mass% or more, still more preferably 0.1 mass% or more, even more preferably 0.2 mass% or more, still more preferably 0.3 mass% or more, and particularly preferably 0.4 mass% or more.
  • Compound (b) in treatment solution A may be added to treatment solution A as a raw material separately from other components in treatment solution A, or may be added to treatment solution A as a component contained in a raw material corresponding to other components in treatment solution A (e.g., compound (a)).
  • the polyhydric alcohol is preferably a polyhydric alcohol having 3 to 6 carbon atoms, more preferably a polyhydric alcohol having 3 to 5 carbon atoms, and even more preferably a polyhydric alcohol having 3 to 4 carbon atoms, and may particularly be a polyhydric alcohol having 3 carbon atoms.
  • the polyhydric alcohol is preferably a dihydric or trihydric polyhydric alcohol, and may particularly be a trihydric polyhydric alcohol.
  • the concentration of the (c) polyhydric alcohol in treatment liquid A is preferably 80% by mass or less, more preferably 3 to 80% by mass, even more preferably 5 to 75% by mass, or 10 to 70% by mass, and particularly preferably 15 to 60% by mass.
  • the concentration of the (c) polyhydric alcohol in treatment liquid A is 0.25 or less, preferably 0.2 or less, more preferably 0.18 or less, even more preferably 0.15 or less, particularly preferably 0.13 or less, and most preferably 0.1 or less.
  • Treatment solution A may contain (d) arginine instead of or in addition to (c) polyhydric alcohol.
  • arginine means preventing the invasion, growth, proliferation, etc. of microorganisms, thereby preventing spoilage and fermentation. Therefore, “preservative effect” refers to the effect of inhibiting the growth of fungi such as molds and bacteria, preventing deterioration of the cosmetic, and improving its shelf life. The preservative effect against mold is sometimes referred to as "antifungal effect.” By including arginine, a preservative effect is achieved, particularly against fungi.
  • fungi examples include molds of the genus Aspergillus (e.g., Aspergillus brasiliensis), the genus Penicillium, and the genus Fusarium, and Candida albicans.
  • arginine it is possible to improve several properties selected from the moisturizing property, adhesion, and durability of the treated powder, and the SPF value of the emulsion formulation when the treated powder is incorporated into the formulation.
  • the concentration of (d) arginine in treatment solution A is preferably 0.5 to 15% by mass, more preferably 0.75 to 10% by mass, or 1.0 to 8% by mass, and even more preferably 1.5 to 7% by mass.
  • the concentration of (d) arginine in treatment solution A is preferably 0.8% by mass or more, more preferably 1.8 to 15% by mass.
  • the mass ratio of the compound (b) to the compound (a) in the treatment solution A is 0.13 or less, and preferably 0.1 or less.
  • treatment solution A contains (c) a polyhydric alcohol and (d) arginine
  • the mass ratio of compound (b) to compound (a) in treatment solution A is preferably 0.2 or less, and preferably 0.17 or less.
  • Treatment solution B preferably contains, as metal ions, ions of one or more metals selected from the group consisting of calcium, zinc, and magnesium, and more preferably contains, as metal ions, ions of one or more metals selected from calcium and zinc.
  • the molar ratio of the metal ion (f) in treatment solution B to the compound (a) in treatment solution A is preferably 0.3 to 10, more preferably 0.35 to 75, even more preferably 0.7 to 5, and particularly preferably 0.7 to 3. By using such a molar ratio, it is possible to obtain a powder that is excellent in multiple properties selected from hydrophobicity, covering power, adhesion, makeup longevity, and the like, and it may also be possible to provide a cosmetic formulation incorporating the powder with an excellent SPF value.
  • treatment liquid A is used in an amount of 0.01 parts by mass or more, preferably 0.1 parts by mass or more, more preferably 5 parts by mass or more, and even more preferably 10 parts by mass or more, relative to 100 parts by mass of powder.
  • Treatment liquid A is used in an amount of 90 parts by mass or less, preferably 70 parts by mass or less, relative to 100 parts by mass of powder.
  • Treatment liquid A may be used in an amount of 0.01 to 70 parts by mass, 0.1 to 70 parts by mass, 1 to 70 parts by mass, 2 to 70 parts by mass, 5 to 70 parts by mass, or 10 to 70 parts by mass.
  • the treatment liquid A may be used in an amount of 0.01 to 50 parts by mass, 0.1 to 50 parts by mass, 1 to 50 parts by mass, 2 to 50 parts by mass, 5 to 50 parts by mass, 1 to 40 parts by mass, 2 to 40 parts by mass, 5 to 40 parts by mass, 5 to 35 parts by mass, 5 to 30 parts by mass, or 5 to 25 parts by mass, relative to 100 parts by mass of the powder.
  • the oil absorption of the powder is not high, for example, the oil absorption per 1 g of powder may be 4 g or less, 3 g or less, or 2 g or less.
  • the mass ratio of the powder to treatment liquid A is preferably 0.1 to 10,000, more preferably 0.1 to 2,000, even more preferably 0.1 to 800, still more preferably 0.1 to 400, particularly preferably 0.5 to 200, and most preferably 1 to 20.
  • the mass ratio of the powder to treatment liquid B is preferably 0.5 to 10,000, more preferably 0.5 to 4,000, even more preferably 0.5 to 2,000, particularly preferably 1 to 400, and most preferably 3 to 100.
  • Treatment liquid B is preferably an aqueous solution having a pH of 9 or less, more preferably an aqueous solution having a pH of 8 or less, even more preferably an aqueous solution having a pH of 7.5 or less, and even more preferably an aqueous solution having a pH of 7 or less.
  • Treatment liquid B may also be an aqueous solution having a weak acidity to alkaline.
  • the pH may be 3 to 9, 3 to 8, 3 to 7.5, 4 to 9, 4 to 8, 4 to 7.5, 4.5 to 9, 4.5 to 8, 4.5 to 7.5, 5 to 9, 5 to 8, or 5 to 7.5.
  • an aqueous citric acid solution, an aqueous tartaric acid solution, lactic acid, an aqueous malic acid solution, an aqueous succinic acid solution, an aqueous ascorbic acid solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, potassium hydroxide, or the like can be used.
  • a pH adjuster that does not inhibit the salt formation between the compound (a) in treatment solution A and the metal ion (f) in treatment solution B, and it is more preferable to use a pH adjuster that does not chelate the metal ion (f) in treatment solution B.
  • lactic acid, an aqueous ascorbic acid solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, or potassium hydroxide may be used.
  • the powder may be surface-treated with silicone, fluorine compound, silane coupling agent, silane, organic titanate, fatty acid, metal soap, oil, amino acid, or the like.
  • Crystalline or amorphous powders such as resin powders, silicon-containing powders, metal oxides, carbon-containing powders, fluorine-containing powders, metal salts, boron-containing powders, and composite powders are preferred in terms of improving water repellency and oil repellency after treatment.
  • the powder may preferably be, for example, talc, mica, sericite, titanium oxide, red iron oxide, yellow iron oxide, black iron oxide, pearl powder, colored pearl pigment.
  • the treatment of the powder in steps (i) and (ii) may be carried out using a mixer selected from high-speed agitation mixers such as a Henschel mixer, FM mixer, high-shear mixer, vertical mixer, or planetary mixer; container rotation mixers or container rotation mixers with agitator such as a W-type mixer, CV-type mixer, V-type mixer, rocking mixer, container mixer, Bohle mixer, or container mixer with a chopper; paddle mixer, ribbon agitation type, double-shaft paddle type, double-shaft planetary agitation type, Nauta mixer, conical screw type mechanical agitation mixer, air current agitation mixer, Julia mixer, and compression/shear/impact mixer such as a Nobilta mixer.
  • high-speed agitation mixers such as a Henschel mixer, FM mixer, high-shear mixer, vertical mixer, or planetary mixer
  • container rotation mixers or container rotation mixers with agitator such as a W-type mixer, CV-type mixer, V
  • the surface treatment agent composition and/or the acidic liquid may be mixed by dropwise addition or spraying.
  • the surface treatment method of the present invention preferably does not include a drying step using power and equipment.
  • step (ii) may be performed after step (i), or step (i) may be performed after step (ii). Also, either or both of step (i) and step (ii) may be performed multiple times. Furthermore, at least a portion of step (i) may be performed simultaneously with step (ii), or at least a portion of step (ii) may be performed simultaneously with step (i).
  • the mixture obtained by mixing treatment liquid A and treatment liquid B contains (c) a polyhydric alcohol and/or (d) arginine, and therefore forms a uniform gel composition with little creaking feeling, thereby improving several properties selected from adhesion, smooth feel, water retention, etc. of the treated powder.
  • the mixture obtained by mixing treatment liquid A and treatment liquid B preferably contains (c) a polyhydric alcohol.
  • the mixture obtained by mixing treatment liquid A and treatment liquid B forms a smooth gel composition on the powder surface, thereby producing a treated powder whose surface is coated with a smooth gel composition.
  • the kinetic friction coefficient of the mixture obtained by mixing treatment liquid A and treatment liquid B is preferably 0.7 or more, more preferably 1.5 or more, and even more preferably 2.0 or more.
  • the kinetic friction coefficient can be measured as an average kinetic friction coefficient using a Tribomaster (trade name: TL201Ts, manufactured by Trinity Labs). Specifically, the composition is thinly applied to artificial leather (manufactured by Idemitsu Technofine Co., Ltd., approximately 2 mm thick) to a concentration of 8.0 mg/ cm2 , and after the mass change reaches equilibrium, it can be measured using a tactile contactor (manufactured by Trinity Lab Co., Ltd., finger model fingerprint type).
  • the measurement conditions for the friction tester are a load of 50 gf, a test table movement speed of 25 mm/sec, and a measurement distance of 25 mm. Furthermore, the moisture retention (%) of a mixture obtained by mixing treatment liquid A and treatment liquid B after allowing it to stand at constant temperature and humidity (23°C, 40% relative humidity (RH)) for one day or more is preferably 8 to 50%, more preferably 8 to 35%, and even more preferably 10 to 25%. The moisture retention can be measured using a Karl Fischer moisture meter.
  • the amount of water when the mass change reaches equilibrium is measured using a Karl Fischer moisture meter, and the amount of water retained (%) of the mixture (a mixture obtained by mixing treatment liquid A and treatment liquid B) can be determined as the ratio of the amount of water retained at constant temperature and humidity to the initial amount of water in the mixture. Furthermore, the amount of water retained at constant temperature and humidity relative to the total mass of compound (a) and compound (b) contained in the mixture can be calculated as the amount of water retained relative to the total mass of compound (a) and compound (b).
  • the powder treatment agent of the present invention contains treatment liquid A and treatment liquid B.
  • the powder treatment agent may be a powder treatment agent in which treatment liquid A and treatment liquid B are mixed, or may be in the form of a kit in which treatment liquid A and treatment liquid B are separately provided.
  • Powders surface-treated by the surface treatment method of the present invention or powders surface-treated with the treatment agent of the present invention are particularly excellent in multiple properties selected from the balance of hydrophilicity and hydrophobicity, makeup durability, evenness, antiseptic effect, moist feel, skin moisture retention effect, ease of dispersion in small amounts of oil, and reduced discoloration due to sebum or sweat. Furthermore, using powders treated by the surface treatment method of the present invention in cosmetic compositions may improve the stability and SPF value of the composition.
  • Powders surface-treated by the surface treatment method of the present invention or powders surface-treated with the treatment agent of the present invention may have a moisture retention (%) of 1 or more, 1.5 or more, or 2 or more when left standing for one day or more under constant temperature and humidity conditions (23°C, 40% relative humidity (RH)).
  • a powder that has been surface-treated by the surface treatment method of the present invention or a powder that has been surface-treated with the treatment agent of the present invention may have a moisture retention (%) that is improved by 50% or more, 100% or more, 150% or more, or 200% or more when left to stand at constant temperature and humidity (23°C, 40% relative humidity (RH)) for one day or more, compared to an untreated powder.
  • the surface-treated powder of the present invention is a powder whose surface is coated with a composition containing: (a) one or more compounds selected from N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof; (b) one or more compounds selected from fatty acids having a carbon chain length of C8 to C22 and salts thereof; (c) a polyhydric alcohol and/or (d) arginine; (e) water; and (f) a metal ion; wherein when the composition does not contain arginine, the mass ratio of compound (b) to compound (a) (compound (b)/compound (a)) is 0.13 or less; and when the composition does not contain a polyhydric alcohol, the mass ratio of compound (b) to compound (a) (compound (b)/compound (a)) is 0.25 or less; and the metal ion (f) comprises an alkaline earth metal ion or a zinc ion.
  • the dynamic friction coefficient can be measured as an average dynamic friction coefficient using a Tribomaster (manufactured by Trinity Labs, product name: TL201Ts). Specifically, the composition is thinly applied to artificial leather (manufactured by Idemitsu Technofine Co., Ltd., thickness approximately 2 mm) to a concentration of 8.0 mg/ cm2 , and after the mass change reaches equilibrium, it can be measured using a tactile contactor (manufactured by Trinity Labs, finger model fingerprint type).
  • the measurement conditions for the friction tester are a load of 50 gf, a test table movement speed of 25 mm/sec, and a measurement distance of 25 mm.
  • the moisture retention (%) of the composition after leaving it at constant temperature and humidity (23°C, 40% relative humidity (RH)) for one day or more is preferably 8 to 50, more preferably 8 to 35, and even more preferably 10 to 25.
  • the moisture retention can be measured using a Karl Fischer moisture meter. Specifically, the moisture content when the mass change reaches equilibrium is measured using a Karl Fischer moisture meter, and the moisture content at constant temperature and humidity relative to the initial moisture content of the composition can be calculated as the moisture retention (%) of the composition (a powder treatment agent obtained by mixing treatment liquid A and treatment liquid B). Furthermore, the moisture content at constant temperature and humidity relative to the total mass of compound (a) and compound (b) contained in the composition can be calculated as the moisture retention relative to the total mass of compound (a) and compound (b).
  • Cosmetic compositions containing powders surface-treated using the surface treatment method of the present invention or cosmetic compositions containing powders surface-treated with the treatment agent of the present invention can be made into any form of cosmetic that can be applied to desired areas (e.g., skin, hair, scalp, lips, eyes, eyelashes, eyelids, nails) using conventional methods.
  • cosmetics for skin, lips, eyelashes, and nails include sunscreens such as sunscreens, body powders, and sprays; makeup cosmetics such as foundations, primers, body colors, bronzers, face powders, nail polishes, cheek colors, makeup bases, and concealers; lip cosmetics such as lip colors, lip liners, and lipsticks; eye makeup cosmetics such as eyeliners, eye shadows, eyebrow makeup, and mascara; leave-on cosmetics such as emulsions, lotions, creams, gels, and serums; and face masks.
  • cosmetics for hair include hair styling products, hair emulsions, hair treatments, hair conditioners, and hair lotions.
  • cosmetics for the scalp include hair growth agents.
  • Preferred cosmetics include, for example, makeup cosmetics, eye makeup cosmetics, lip cosmetics, and leave-on cosmetics.
  • Preferred topical preparations include, for example, ointments, creams, mousses, and gels.
  • the present inventors have found for the first time that a powder surface can be treated with a uniform gel in a simple manner by using a treatment solution A containing an N-acylamino acid or a salt thereof having an acyl group with a carbon chain length of 8 to C22 and a polyhydric alcohol, and a treatment solution B which is an aqueous solution containing metal ions. Therefore, in another aspect of the present invention, the method for treating a powder surface of the present invention comprises the following steps: The method includes (i) a step of treating a powder with a treatment liquid A, and (ii) a step of treating a powder with a treatment liquid B.
  • treatment liquid A contains the following components: (a) one or more compounds selected from N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof; (c) a polyhydric alcohol; (e) water.
  • component (c) in treatment liquid A, the treatment agent containing treatment liquid A and treatment liquid B forms a uniform gel composition, and the treatment agent containing treatment liquid A and treatment liquid B can treat the surface of the powder with a uniform gel.
  • Another aspect of the present invention is a surface treatment agent for powder, comprising one or more compounds selected from the following group: N-acylamino acids or salts thereof, and (b') one or more fatty acids and salts thereof.
  • the N-acylamino acid preferably includes N-acylglycine and N-acylglutamic acid.
  • the N-acylamino acid is preferably an N-acylamino acid having an acyl group with a carbon chain length of C8 to C22.
  • the salt of the N-acylamino acid is preferably a metal salt.
  • the metal salt is preferably a sodium salt or a potassium salt.
  • the total content of these in the surface treatment agent of this embodiment is preferably 5 to 40% by mass, and more preferably 10 to 30% by mass.
  • the surface treatment agent of this embodiment may have lyotropic liquid crystals such as lamellar liquid crystals or hexagonal liquid crystals.
  • N-acylglycine when N-acylglycine is used as the N-acylamino acid, if an N-acylglycine having a saturated or unsaturated linear acyl group is used, the structure of the surface treatment composition containing the surface treatment agent of this embodiment will form a lamellar structure, whereas if an N-acylglycine having a branched acyl group is used, the structure of the surface treatment composition containing the surface treatment agent of this embodiment will form a hexagonal structure. Due to these structural differences, powders whose surfaces have been treated with the surface treatment agent of this embodiment exhibit good tactile sensations such as softness, spreadability, and smoothness, and the tactile sensation of the powders surface-treated with the surface treatment agent of this embodiment can be controlled.
  • the fatty acid of compound (b') is preferably a fatty acid having a carbon chain length of C8 to C22.
  • the pH of the surface treatment agent of this embodiment is preferably 7 to 13, and more preferably 8 to 12.
  • the surface treatment agent of this embodiment may further contain an oil.
  • the surface treatment agent of this embodiment may have the features of the above-described respective embodiments of the present invention. Another aspect of the present invention may be as follows.
  • a method for producing a surface-treated powder comprising: (i') a step of treating a powder with a treatment liquid A'; and (ii') a step of treating the powder with a treatment liquid B,
  • the treatment solution A' contains (a') one or more compounds selected from N-acylglycine or a salt thereof, (a'') one or more compounds selected from N-acylglutamic acid or a salt thereof, (b') one or more compounds selected from fatty acids and salts thereof, and (e) water;
  • the treatment liquid B is (f) an aqueous solution containing metal ions, The method of manufacturing, wherein the metal ions (f) include ions of alkaline earth metals or ions of zinc.
  • [15'] The method for producing a photosensitive material according to any one of the above [1'] to [14'], wherein the mass ratio of the powder to the treatment liquid A' is 0.1 to 200.
  • [16'] The manufacturing method according to any one of the above [1'] to [15'], wherein the mass ratio of the powder to the treatment liquid B is 0.5 to 1000.
  • [17'] The manufacturing method according to any one of the above [1'] to [16'], wherein the mass ratio of the total mass of the compound (a'), the compound (a"), and the compound (b') in the treatment liquid A' to the powder is 0.1 mass% or more.
  • [18'] The method for producing a film according to any one of [1'] to [17'] above, wherein the mixture obtained by mixing the treatment liquid A' and the treatment liquid B forms a gel composition.
  • [19'] A surface-treated powder obtained by the manufacturing method described in any one of [1'] to [18'], [53b'] and [53c'] above.
  • [20'] A cosmetic composition containing the surface-treated powder according to [19'] above.
  • a powder treatment agent containing treatment liquid A' and treatment liquid B contains (a') one or more compounds selected from N-acylglycine or a salt thereof, (a'') one or more compounds selected from N-acylglutamic acid or a salt thereof, (b') one or more compounds selected from fatty acids and salts thereof, and (e) water;
  • the treatment liquid B is (f) an aqueous solution containing metal ions, A treatment agent wherein the metal ions (f) include ions of alkaline earth metals or ions of zinc.
  • [35'] The treatment agent according to any one of the above [21′] to [34′], which is used for treatment in a powder to treatment liquid A′ mass ratio of 0.1 to 200.
  • [36'] The treatment agent according to any one of the above [21'] to [35'], which is used for treatment in a mass ratio of powder to treatment liquid B of 0.5 to 1000.
  • [37'] The treatment agent according to any one of the above [21'] to [36'], wherein the mass ratio of the total mass of the compound (a'), the compound (a"), and the compound (b') in the treatment liquid A' to the powder is 0.1 mass% or more.
  • [38'] The treatment agent according to any one of [21'] to [37'] above, wherein the mixture obtained by mixing treatment liquid A' and treatment liquid B forms a gel composition.
  • [39'] A powder surface-treated with the treating agent according to any one of [21'] to [38'], [53d'] and [53e'].
  • [40'] A cosmetic composition containing the powder described in [39'] above.
  • examples of the acyl component constituting the N-acyl group of N-acylglycine include acyl groups derived or derivable from linear or branched, saturated or unsaturated fatty acids having 8 to 22 carbon atoms, such as single fatty acid acyl groups such as octanoyl, caproyl, nonanoyl, caprinoyl, decanoyl, undecanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, arachidinoyl, behenoyl, palmitoleoyl, oleoyl, and linoleoyl groups, naturally occurring mixed fatty acid acyl groups such as coconut oil fatty acid acyl and hardened beef tallow fatty acid acyl, as well as aromatic carboxylic acid acyl groups such as benzoic acid acyl.
  • the acyl group of an N-acylamino acid having an acyl group with a carbon chain length of C8 to C22 may be an octanoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, behenoyl group, palmitoleyl group, oleoyl group, linoleoyl group, or coconut oil fatty acyl, of which an octanoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, palmitoleyl group, oleoyl group, or linoleoyl group is preferred, an octanoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, or coconut oil fatty acyl is more preferred, and an oc
  • N-acylglycines and salts thereof include octanoylglycine, sodium octanoylglycine, potassium octanoylglycine, decanoylglycine, sodium decanoylglycine, potassium decanoylglycine, lauroylglycine, sodium lauroylglycine, potassium lauroylglycine, myristoylglycine, sodium myristoylglycine, potassium myristoylglycine, palmitoylglycine, sodium palmitoylglycine, potassium palmitoylglycine, and stearoylglycine.
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include palmitoyl glutamic acid, sodium palmitoyl glutamate, disodium palmitoyl glutamate, potassium palmitoyl glutamate, dipotassium palmitoyl glutamate, ammonium palmitoyl glutamate, triethanolamine palmitoyl glutamate, stearoyl glutamic acid, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearo ...
  • palmitoyl glutamic acid sodium palmitoyl glutamate, disodium palmitoyl glutamate, potassium palmitoyl glutamate, dipotassium palmitoyl glutamate, stearoyl glutamic acid, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearoyl glutamate, or dipotassium stearoyl glutamate may be used.
  • the use of these N-acyl glutamic acids can improve several properties selected from the hydrophobicity of the treated powder, a pleasant feel, and low-temperature stability of the treatment liquid.
  • the concentration of compound (a") in treatment liquid A' is preferably 0.15% by mass or more, more preferably 0.25% by mass or more, even more preferably 0.5% by mass or more, and particularly preferably 1.0% by mass or more.
  • the concentration of compound (a") in treatment liquid A' is preferably 36% by mass or less, more preferably 20% by mass or less, even more preferably 16% by mass or less, and particularly preferably 10% by mass or less.
  • the concentration of compound (a”) in treatment liquid A' may be preferably 0.15 to 36% by mass, more preferably 0.25 to 20% by mass, even more preferably 0.5 to 16% by mass, and particularly preferably 1.0 to 10% by mass.
  • the fatty acid that is compound (b') may be a straight-chain fatty acid or a branched-chain fatty acid, with straight-chain fatty acids being preferred. It may be a saturated or unsaturated fatty acid, with saturated fatty acids being preferred.
  • the fatty acid may be a fatty acid having a carbon chain length of C8 to C22, with fatty acids having a carbon chain length of C8 to C20 being preferred, fatty acids having a carbon chain length of C8 to C18 being more preferred, and fatty acids having a carbon chain length of C8 to C14 being even more preferred.
  • fatty acids having a carbon chain length of C8 to C22 include octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, eicosenoic acid, erucic acid, hardened beef tallow fatty acid, coconut oil fatty acid, and palm oil fatty acid.
  • Fatty acids having a carbon chain length of C8 to C22 are preferably octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidic acid, oleic acid, and coconut oil fatty acid, more preferably octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, and coconut oil fatty acid, and even more preferably octanoic acid, decanoic acid, lauric acid, myristic acid, and coconut oil fatty acid.
  • salts of fatty acids having a carbon chain length of C8 to C22 include pharmacologically acceptable salts, such as alkali metal salts (e.g., lithium salts, sodium salts, and potassium salts); alkaline earth metal salts (e.g., calcium salts and magnesium salts); ammonium salts; basic organic salts; triethanolamine salts; and the like.
  • alkali metal salts e.g., lithium salts, sodium salts, and potassium salts
  • alkaline earth metal salts e.g., calcium salts and magnesium salts
  • ammonium salts e.g., sodium salts, potassium salts, and ammonium salts are preferred from the viewpoint of solubility, with sodium salts and potassium salts being more preferred, and potassium salts being even more preferred.
  • the fatty acid having a carbon chain length of C8 to C22, which is compound (b'), preferably has a partition coefficient of 10 or less, more preferably 8.5 or less.
  • the concentration of compound (b') in treatment liquid A' is preferably 0.25% by mass or more, more preferably 0.5% by mass or more, even more preferably 1.0% by mass or more, and particularly preferably 2.0% by mass or more.
  • the concentration of compound (b') in treatment liquid A' is preferably 37% by mass or less, more preferably 24% by mass or less, even more preferably 20% by mass or less, and particularly preferably 15% by mass or less.
  • the concentration of compound (b') in treatment liquid A' may be preferably 0.25 to 37% by mass, more preferably 0.5 to 24% by mass, even more preferably 1 to 20% by mass, and particularly preferably 2.0 to 15% by mass or less.
  • the compound (b') in the treatment solution A' may be added to the treatment solution A' as a raw material separately from the other components in the treatment solution A', or may be added to the treatment solution A' as a component contained in a raw material corresponding to the other components in the treatment solution A' (e.g., the compound (a') and/or the compound (a")).
  • the total concentration of the compound (a'), the compound (a"), and the compound (b') in the treatment liquid A' is preferably 5 to 40 mass%, more preferably 10 to 35 mass%, even more preferably 10 to 30 mass%, and particularly preferably 20 to 30 mass%.
  • the mass proportion of compound (a') relative to the total mass of compound (a'), compound (a"), and compound (b') in treatment liquid A' is preferably 5 to 92 mass%, more preferably 10 to 90 mass%, even more preferably 30 to 80 mass%, and still more preferably 40 to 70 mass%.
  • the mass proportion of the compound (a") relative to the total mass of the compound (a"), the compound (a"), and the compound (b") in the treatment liquid A' is preferably 3 to 90 mass%, more preferably 3 to 50 mass%, even more preferably 5 to 40 mass%, and still more preferably 10 to 40 mass%.
  • the mass proportion of compound (b') relative to the total mass of compound (a'), compound (a"), and compound (b') in treatment liquid A' is preferably 5 to 92 mass%, more preferably 5 to 60 mass%, even more preferably 10 to 60 mass%, and still more preferably 20 to 50 mass%.
  • the mass proportion of compound (a') relative to the total mass of compound (a'), compound (a"), and compound (b') in treatment liquid A' is 5 to 92 mass%, more preferably 10 to 90 mass%, even more preferably 30 to 80 mass%, and even more preferably 40 to 70 mass%, and the mass proportion of compound (a") is 3 to 90 mass%, more preferably 3 to 50 mass%, even more preferably 5 to 40 mass%, and even more preferably 10 to 40 mass%.
  • the mass proportion of compound (a') relative to the total mass of compound (a'), compound (a"), and compound (b') in treatment liquid A' is 5 to 92 mass%, more preferably 10 to 90 mass%, even more preferably 30 to 80 mass%, and even more preferably 40 to 70 mass%, and the mass proportion of compound (b') is 5 to 92%, more preferably 5 to 60 mass%, even more preferably 10 to 60 mass%, and even more preferably 20 to 50 mass%.
  • the mass proportion of compound (a") relative to the total mass of compound (a'), compound (a"), and compound (b') in treatment liquid A' is 3 to 90 mass%, more preferably 3 to 50 mass%, even more preferably 5 to 40 mass%, and even more preferably 10 to 40 mass%, and the mass proportion of compound (b') is 5 to 92 mass%, more preferably 5 to 60 mass%, even more preferably 10 to 60 mass%, and even more preferably 20 to 50 mass%.
  • a pH adjuster is used that does not inhibit the salt formation between compound (a') and/or compound (a") in treatment solution A' and metal ion (f) in treatment solution B, and more preferably, a pH adjuster that does not chelate metal ion (f) in treatment solution B.
  • Lactic acid, aqueous ascorbic acid, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, potassium hydroxide, arginine, or lysine is even more preferred, with sodium hydroxide, potassium hydroxide, and arginine being particularly preferred.
  • the mass ratio of the metal ion (f) in the treatment solution B to the total mass of the compound (a'), compound (a"), and compound (b') in the treatment solution A' is preferably 0.01 to 1, more preferably 0.04 to 0.5, even more preferably 0.06 to 0.35, and particularly preferably 0.08 to 0.25.
  • the mass ratio of the powder to the treatment liquid B is preferably 0.5 to 1000, more preferably 4 to 500, even more preferably 6 to 250, still more preferably 8 to 160, particularly preferably 13 to 120, and most preferably 20 to 80.
  • the mass ratio of the total mass of the compound (a'), the compound (a"), and the compound (b') in the treatment liquid A' to the powder is preferably 0.1 mass% or more, more preferably 0.5 mass% or more, even more preferably 1.0 mass% or more, and particularly preferably 1.5 mass% or more.
  • Treatment solution B contains (f) metal ions, and the metal ions (f) include alkaline earth metal ions or zinc ions, preferably alkaline earth metal ions or zinc ions.
  • the metal ions (f) include magnesium ions, calcium ions, and zinc ions.
  • Examples of compounds that generate such ions include magnesium hydroxide, magnesium chloride, magnesium sulfate, magnesium nitrate, magnesium potassium sulfate, calcium hydroxide, calcium chloride, calcium nitrate, calcium acetate, zinc chloride, zinc nitrate, zinc sulfate, and zinc acetate.
  • Treatment solution B preferably contains, as metal ions, ions of one or more metals selected from the group consisting of calcium, zinc, and magnesium, and more preferably contains, as metal ions, ions of one or more metals selected from calcium and zinc.
  • treatment liquid B synergistically enhances the antifungal effect of treatment liquid A'.
  • the treatment liquid B preferably has a transmittance of 60% or more, more preferably 80% or more, at a wavelength of 660 nm. By setting the transmittance of treatment liquid B within this range, the hydrophobicity and pleasant feel of the treated powder can be improved.
  • Treatment liquid A' may be used in an amount of 0.5 to 1000 parts by mass, 1 to 100 parts by mass, 2.5 to 50 parts by mass, 5 to 40 parts by mass, 7.5 to 30 parts by mass, or 10 to 25 parts by mass. Using treatment liquid A' in such an amount can improve several properties of the treated powder selected from hydrophobicity, preferable feel, and the like.
  • the mass ratio of the powder to the treatment liquid A' is 0.1 to 200, preferably 1.0 to 100, more preferably 2 to 40, even more preferably 2.5 to 20, and particularly preferably 3.0 to 15.
  • the treatment liquid A' in such an amount, it is possible to improve several properties selected from the hydrophobicity of the treated powder, the preferable feel, and the like.
  • the mass ratio of the powder to treatment liquid B is preferably 0.5 to 1000, more preferably 4 to 500, even more preferably 6 to 250, still more preferably 8 to 160, particularly preferably 13 to 120, and most preferably 20 to 80.
  • Treatment liquid B is preferably an aqueous solution having a pH of 9.0 or less, more preferably an aqueous solution having a pH of 8.0 or less, even more preferably an aqueous solution having a pH of 7.5 or less, and even more preferably an aqueous solution having a pH of 7 or less.
  • Treatment liquid B may also be an aqueous solution that is weakly acidic to alkaline.
  • the pH may be 3.0 to 9.0, 3.0 to 8.0, 3.0 to 7.5, 4.0 to 9.0, 4.0 to 8.0, 4.0 to 7.5, 4.5 to 9.0, 4.5 to 8.0, 4.5 to 7.5, 5.0 to 9.0, 5.0 to 8.0, or 5.0 to 7.5.
  • the pH can be adjusted using an aqueous citric acid solution, an aqueous tartaric acid solution, lactic acid, an aqueous malic acid solution, an aqueous succinic acid solution, an aqueous ascorbic acid solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, potassium hydroxide, or the like. It is preferable to use a pH adjuster that does not inhibit the salt formation between compound (a'), compound (a"), or compound (b') of treatment solution A' and metal ion (f) of treatment solution B, and it is more preferable to use a pH adjuster that does not chelate metal ion (f) of treatment solution B. It is even more preferable to use lactic acid, an aqueous ascorbic acid solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, or potassium hydroxide.
  • the powder used in the surface treatment method of the present invention is not particularly limited as long as it is used for industrial purposes or cosmetics (pigments, coloring matters, resins, pearls), and examples thereof include resin powders such as nylon powder, nylon beads, silicone beads, and polyethylene beads; Metal oxides such as iron oxide (yellow pigment), iron oxide (red pigment), iron oxide (black pigment), tin oxide, chromium oxide, cobalt oxide, zinc oxide, pigment-grade zinc oxide, titanium oxide, pigment-grade titanium oxide, zirconium oxide, aluminum oxide, cerium oxide, fine particle titanium oxide, ultrafine particle titanium oxide, fine particle zinc oxide, and fine particle iron oxide; silicon-containing powders such as silicates (silicate (Al/Ca/Na), silicate (Na/Mg)), sericite, mica, talc, kaolin, bentonite, aluminum silicate, magnesium silicate, cubic sodium aluminosilicate, silicon carbide, hydrous silica, and silicon oxides such as silicic anhydride (lea
  • the powder may be surface-treated with silicone, fluorine compound, silane coupling agent, silane, organic titanate, fatty acid, metal soap, oil, amino acid, or the like.
  • Crystalline or amorphous powders such as resin powders, silicon-containing powders, metal oxides, carbon-containing powders, fluorine-containing powders, metal salts, boron-containing powders, and composite powders are preferred in terms of improving water repellency and oil repellency after treatment.
  • the powder may preferably be, for example, talc, mica, sericite, titanium oxide, red iron oxide, yellow iron oxide, black iron oxide, pearl powder, colored pearl pigment.
  • the treatment of the powder in steps (i') and (ii') may be carried out using a mixer selected from high-speed agitation mixers such as a Henschel mixer, FM mixer, high-shear mixer, vertical mixer, or planetary mixer; container rotation mixers or container rotation mixers with agitator such as a W-type mixer, CV-type mixer, V-type mixer, rocking mixer, container mixer, Bohle mixer, or container mixer with a chopper; paddle mixer, ribbon agitation type, double-shaft paddle type, double-shaft planetary agitation type, Nauta mixer, conical screw type mechanical agitation mixer, air current agitation mixer, Julia mixer, and compression/shear/impact mixer such as a Nobilta.
  • high-speed agitation mixers such as a Henschel mixer, FM mixer, high-shear mixer, vertical mixer, or planetary mixer
  • container rotation mixers or container rotation mixers with agitator such as a W-type mixer, CV-type mixer,
  • the surface treatment agent composition and/or the acidic liquid may be mixed by dropwise addition or spraying.
  • the method for producing the surface-treated powder of the present invention preferably does not include a drying step that requires power and equipment.
  • step (ii') may be performed after step (i'), or step (i') may be performed after step (ii').
  • step (ii') may be performed after step (ii').
  • step (ii') may be performed multiple times.
  • at least a portion of step (i') may be performed simultaneously with step (ii'), or at least a portion of step (ii') may be performed simultaneously with step (i').
  • the mixture obtained by mixing treatment liquid A' and treatment liquid B forms a gel-like composition with less squeaky feeling, and can improve several properties selected from the smooth feel and good spreadability of the treated powder.
  • the mixture obtained by mixing treatment liquid A' and treatment liquid B forms a smooth gel-like composition on the surface of the powder, making it possible to produce treated powder whose surface is coated with a smooth gel-like composition.
  • a powder obtained by the method for producing a surface-treated powder of the present invention or a powder surface-treated with the treatment agent of the present invention can also be said to be a powder whose surface is coated with a composition containing the (a') one or more compounds selected from N-acylglycines or salts thereof, the (a") one or more compounds selected from N-acylglutamic acids or salts thereof, the (b') one or more compounds selected from fatty acids and salts thereof, the (e) water, and the (f) metal ions (including alkaline earth metal ions or zinc ions).
  • the characteristics of each component in this powder can be the same as those of the corresponding component described above.
  • the mass ratio of compound (a") in the composition to the total mass of compound (a'), compound (a"), and compound (b') in the composition is preferably 3 mass% or more, more preferably 5 mass% or more, and even more preferably 10 mass% or more.
  • the mass ratio is preferably 90 mass% or less, more preferably 50 mass% or less, and even more preferably 40 mass% or less.
  • the mass ratio may be preferably 3 to 90 mass%, more preferably 5 to 50 mass%, and even more preferably 10 to 40 mass%.
  • the mass ratio of compound (b') in the composition to the total mass of compound (a'), compound (a"), and compound (b') in the composition is preferably 5 mass% or more, more preferably 10 mass% or more, and even more preferably 20 mass% or more.
  • the mass ratio is preferably 92 mass% or less, more preferably 90 mass% or less, even more preferably 60 mass% or less, and particularly preferably 50 mass% or less.
  • the mass ratio may be preferably 5 to 92 mass%, more preferably 5 to 90 mass%, even more preferably 10 to 60 mass%, and particularly preferably 20 to 50 mass%.
  • the mass ratio of compound (a") to the total mass of compound (a'), compound (a"), and compound (b') in the composition is preferably 3 mass% or more, more preferably 5 mass% or more, and even more preferably 10 mass% or more.
  • the mass ratio is preferably 90 mass% or less, more preferably 50 mass% or less, and even more preferably 40 mass% or less.
  • the mass ratio may also be preferably 3 to 90 mass%, more preferably 5 to 50 mass%, and even more preferably 10 to 40 mass%.
  • the mass ratio of compound (a") in the composition to the total mass of compound (a'), compound (a"), and compound (b') in the composition is preferably 3 mass% or more, more preferably 5 mass% or more, and even more preferably 10 mass% or more.
  • the mass ratio is preferably 90 mass% or less, more preferably 50 mass% or less, and even more preferably 40 mass% or less.
  • the mass ratio may be preferably 3 to 90 mass%, more preferably 5 to 50 mass%, and even more preferably 10 to 40 mass%.
  • the mass ratio of compound (a') in the composition to the total mass of compound (a'), compound (a"), and compound (b') in the composition is preferably 5 mass% or more, more preferably 10 mass% or more, even more preferably 30 mass% or more, and particularly preferably 40 mass% or more.
  • the mass ratio is preferably 92 mass% or less, more preferably 90 mass% or less, even more preferably 80 mass% or less, and particularly preferably 70 mass% or less.
  • the mass ratio may be preferably 3 to 90 mass%, more preferably 5 to 50 mass%, and even more preferably 10 to 40 mass%. Furthermore, the mass ratio of compound (b') in the composition relative to the total mass of compound (a'), compound (a"), and compound (b') in the composition is preferably 5 mass% or more, more preferably 10 mass% or more, and even more preferably 20 mass% or more. The mass ratio is preferably 92 mass% or less, more preferably 90 mass% or less, even more preferably 60 mass% or less, and particularly preferably 50 mass% or less. The mass ratio may be preferably 5 to 92 mass%, more preferably 5 to 90 mass%, even more preferably 10 to 60 mass%, and particularly preferably 20 to 50 mass%.
  • cosmetics for skin, lips, eyelashes, and nails include sunscreens such as sunscreen, body powder, and sprays; makeup cosmetics such as foundation, primer, body color, bronzer, face powder, nail polish, cheek color, makeup base, and concealer; lip cosmetics such as lip color, lip liner, and lipstick; eye makeup cosmetics such as eyeliner, eye shadow, eyebrow makeup, and mascara; leave-on cosmetics such as emulsions, lotions, creams, gels, and serums; and face masks.
  • cosmetics for hair include hair styling products, hair emulsions, hair treatments, hair conditioners, and hair lotions.
  • cosmetics for the scalp include hair growth agents.
  • Preferred cosmetics include makeup cosmetics, eye makeup cosmetics, lip cosmetics, and leave-on cosmetics.
  • Preferred topical preparations include ointments, creams, mousses, and gels.
  • dispersants include natural gums such as gum arabic and gum tragacanth, glucosides such as saponin, cellulose derivatives such as methyl cellulose, carboxy cellulose and hydroxymethyl cellulose, natural polymers such as lignin sulfonates and shellac, anionic polymers such as polyaspartates, polyacrylates, salts of styrene-acrylic acid copolymers, salts of vinylnaphthalene-maleic acid copolymers, sodium salts of ⁇ -naphthalenesulfonic acid formalin condensates, and phosphates, and nonionic polymers such as polyvinyl alcohol, polyvinylpyrrolidone and polyethylene glycol;
  • acyl groups can be derived from fatty acids, they can also be derived from raw materials other than fatty acids (fatty acid esters, fatty acid salts, acid halides, acid anhydrides, etc.).
  • the constituent amino acids include the above-mentioned acidic amino acids such as aspartic acid, or amino acids such as alanine, valine, leucine, isoleucine, proline, methionine, cysteine, tryptophan, tyrosine, phenylalanine, asparagine, glutamine, serine, threonine, oxyproline, ⁇ -aminopropionic acid, ⁇ -aminobutyric acid, anthranilic acid, m-aminobenzoic acid, and p-aminobenzoic acid, or salts thereof, alkyl ether carboxylates, amide ether carboxylates, alkyl sulfates (AS), polyoxyethylene alkyl ether sulfates (A
  • PEG-10 hydrogenated castor oil PEG-20 hydrogenated castor oil, PEG
  • Polyoxyethylene hydrogenated castor oil derivatives such as POE hydrogenated castor oil triisostearate, POE hydrogenated castor oil monopyroglutamic acid monoisostearate diester, and POE hydrogenated castor oil maleic acid; POE castor oil 3, POE castor oil 4, POE castor oil 6, POE castor oil 7, POE castor oil 10, POE castor oil 13.5, POE castor oil 17, POE castor oil 20, and POE Polyoxyethylene castor oil derivatives such as castor oil 25, POE castor oil 30, POE castor oil 35, and POE castor oil 50; polyoxyethylene sorbitan fatty acid esters such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, and polysorbate 85; polyoxyethylene sorbitol monolaurate; polyoxyethylene sorbitol Polyoxyethylene sorbitol fatty acid esters such as polyoxyethylene sorbitol monooleate, polyoxyethylene sorbitol pentaoleate
  • propylene glycol monostearate and other propylene glycol mono fatty acid esters pentaerythritol partial fatty acid esters, sorbitol partial fatty acid esters, maltitol partial fatty acid esters, maltitol ethers, diglycerol sorbitan penta-2-ethylhexylate, diglycerol sorbitan tetra-2-ethylhexylate, sorbitan coconut fatty acid, sorbitan laurate, sorbitan oleate, sorbitan stearate, sorbitan isostearate, sorbitan olivate fatty acid, sorbitan sesquiisostearate, sorbitan sesquioleate, sorbitan sesquistearate, sorbitan trioleate, sorbitan tristearate, sorbitan palmitate, and the like.
  • Sorbitan fatty acid esters sucrose distearate, sucrose stearate, sucrose palmitate, sucrose laurate, sucrose polystearate and other fatty acid esters, methyl glucoside fatty acid esters, partial esters of sugar derivatives such as trehalose undecylenate, octyl glucoside, nonyl glucoside, decyl glucoside, dodecyl glucoside, myristyl glucoside, palmityl glucoside, (C12-20) alkyl glucoside, arachidyl glucoside, arachidyl glucoside, (caprylyl/capryl) glucoside, cetearyl glucoside, coconut oil alkyl glucoside, alkyl glycosides such as lauryl glucoside, alkyl polyglycosides, lanolin alcohols , reduced lanolins, polyoxyethylene propylene glycol fatty acid esters
  • Hydrocarbons such as paraffin, liquid paraffin, heavy liquid paraffin, light liquid paraffin, petrolatum, ceresin, microcrystalline wax, isoparaffin, ozokerite, squalene, pristane, squalane, isododecane, and isohexadodecane; waxes such as beeswax, spermaceti, lanolin, carnauba wax, candelilla wax, cotton wax, bayberry wax, ivory wax, montan wax, rice bran wax, koji wax, lanolin acetate, liquid lanolin, sugarcane wax, isopropyl lanolinate, hexyl laurate, hydrogenated jojoba oil, reduced lanolin, jojoba wax, hard lanolin, shellac wax, polyoxyethylene cholesterol ether, polyoxyethylene lanolin alcohol ether, polyoxyethylene lanolin alcohol acetate, lanolin fatty acid polyethylene glycol, polyoxyethylene hydrogenated lanolin alcohol ether
  • Higher fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, behenic acid, undecylenic acid, 12-hydroxystearic acid, palmitoleic acid, oleic acid, lanolin fatty acids, hard lanolin fatty acids, soft lanolin fatty acids, linoleic acid, linolenic acid, erucic acid, docosahexaenoic acid, eicosapentaenoic acid, isohexadecanoic acid, anteisohenicosanoic acid, 12-hydroxystearic acid, long-chain branched fatty acids, dimer acids, hydrogenated dimer acids, and their aluminum salts, calcium salts, magnesium salts, zinc salts, potassium salts, and other metal soaps, as well as nitrogen-containing derivatives such as amides; lauryl alcohol Higher alcohols such as hexyldecanol, octyld
  • Volatile and non-volatile silicones such as dimethylpolysiloxane, polyether-modified silicone, alcohol-modified silicone, methylphenylpolysiloxane, epoxy-modified silicone, fluorine-modified silicone, alkyl-modified silicone, alkoxy-modified silicone, amino-modified silicone, polymeric silicone, volatile silicone, and cyclic silicone; polyols such as glycerin, diglycerin, polyglycerin, 1,3-butanediol, propanediol, and polyethylene glycol;
  • Moisturizing agents such as alkylglycines (e.g., N-methylglycine, N,N-dimethylglycine, N,N,N-trimethylglycine, N-ethylglycine, glycylbetaine), sorbitol, raffinose, pyrrolidone carboxylates, lactates, hyaluronates, ceramides, (poly)saccharides (e.g., trehalose, xylobiose, maltose, sucrose, glucose, and plant mucilage polysaccharides) and their derivatives, glycosaminoglycans (e.g., water-soluble chitin, chitosan, pectin, and chondroitin sulfate and their salts), amino acids (e.g., glycine, serine, threonine, alanine, aspartic acid, tyrosine, valine
  • Thickening and foam-increasing ingredients such as cationic cellulose derivatives, cationic starch, cationic guar gum derivatives, diallyl quaternary ammonium salt/acrylamide copolymers, quaternized polyvinylpyrrolidone derivatives, quaternized vinylpyrrolidone/vinylimidazole polymers, polyglycol/amine condensates, quaternized collagen polypeptides, polyethyleneimine, cationic silicone polymers, adipic acid/dimethylaminohydroxypropyldiethylenetriamine copolymers, polyaminopolyamides, cationic chitin derivatives, cationic polymers such as quaternized polymers, polyethylene glycol fatty acid esters, polyoxyethylene fatty acid ester methylglycosides, and tetradecene sulfonates;
  • Oil gelling agents such as dextrin fatty acid esters, glycerin fatty acid esters, and hydroxystearic acid; sequestering agents such as ethylenediaminetetraacetic acid and its salts, hydroxyethylenediaminetriacetic acid and its salts, phosphoric acid, ascorbic acid, succinic acid, gluconic acid, polyphosphates, metaphosphates, and hinokitils;
  • Antiseptics and antibacterial agents such as parahydroxybenzoic acid esters, benzoic acid and its salts, phenoxyethanol, hinokitiol, salicylic acid and its salts, sorbic acid and its salts, dehydroacetic acid and its salts, parachlormetacresol, hexachlorophene, boric acid, resorcinol, tribromosalan, o-phenylphenol, thiram, photosensitizer No.
  • pH adjusters such as citric acid, malic acid, adipic acid, glutamic acid, and aspartic acid
  • other anti-dandruff and anti-itch agents such as trichlorocarbanilide, salicylic acid, zinc pyrithione, isopropyl methyl, and phenol
  • Benzoic acid-based UV absorbers such as para-aminobenzoic acid, para-aminobenzoic acid monoglycerin ester, N,N-dipropoxypara-aminobenzoic acid ethyl ester, N,N-diethoxypara-aminobenzoic acid ethyl ester, N,N-dimethylpara-aminobenzoic acid ethyl ester, N,N-dimethylpara-aminobenzoic acid butyl ester, and N,N-dimethylpara-aminobenzoic acid ethyl ester; anthranilic acid-based UV absorbers such as homomenthyl-N-acetylanthranilate; salicylic acid-based UV absorbers such as salicylic acid and its sodium salt, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzy
  • Ascorbic acid and its salts alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, magnesium salt, calcium salt, as well as ammonium salt, amino acid salt, etc.
  • ascorbic acid derivatives L-ascorbic acid alkyl ester, L-ascorbic acid phosphate ester and its salt, L-ascorbic acid-2-sulfate ester and its salt, L-ascorbic acid glucoside, etc.
  • alkoxysalicylic acid and its salt alkoxy groups include, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, etc.), hydroquinone glycosides and their derivatives (arbutin, etc.), kojic acid and its derivatives, ellagic acid, chamomile extract, althea extract, licorice extract, mulberry bark extract, raspberry extract, apple flavonoids, bran extract, vitamin E and its derivatives, hin
  • Circulation promoters such as Swertia japonica extract, cepharanthine, vitamin E and its derivatives, and gamma oryzanol; topical stimulants such as capsicum tincture, angelica rhododendron tincture, cantharides tincture, and nicotinic acid benzyl ester; nutrients such as various vitamins and amino acids; female hormones; hair root activators;
  • Anti-inflammatory agents such as ricyrrhizinic acid, glycyrrhizinic acid derivatives, allantoin, azulene, aminocaproic acid, and hydrocortisone; astringents such as zinc oxide, zinc sulfate, allantoin hydroxyaluminum, aluminum chloride, aluminum sulfate, zinc sulfocarbonate, tannic acid, citric acid, and lactic acid; cooling agents such as menthol and camphor; antihistamines such as diphenhydramine hydrochloride, chlorpheniramine maleate, and glycyrrhizinic acid derivatives;
  • Antioxidants such as tocopherols, BHA, BHT, gallic acid, and NDGA; sebum suppressants such as estradiol, estrone, and ethinyl estradiol; exfoliants and dissolvers such as sulfur, salicylic acid, and resorcinol; alpha-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid; and beta-hydroxy acids such as salicylic acid.
  • sebum suppressants such as estradiol, estrone, and ethinyl estradiol
  • exfoliants and dissolvers such as sulfur, salicylic acid, and resorcinol
  • alpha-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid
  • beta-hydroxy acids such as salicylic acid.
  • the surface treatment agent for powder contains one or more N-acylamino acids or salts thereof.
  • the N-acylamino acid may be one or more selected from N-acylalanine, N-acyltreonine, N-acylglutamic acid, N-acylproline, N-acylarginine, and N-acyllysine.
  • the surface treatment agent of this embodiment may further contain a nonionic surfactant.
  • the pH of the surface treatment agent of this embodiment is preferably 7 or higher.
  • the surface treatment agent for powder contains one or more selected from N-acylalanine, N-acyl-N-methyl- ⁇ -alanine, N-acyl-N-methyltaurine, N-acylsarcosine, cocoamphoacetic acid, and metal salts thereof.
  • the surface treatment agent of this embodiment may further contain a nonionic surfactant, a cationic surfactant, and/or an amphoteric surfactant.
  • the surface treatment agent of this embodiment may have the features of the above-described respective embodiments of the present invention.
  • the compound (a''') is a powder surface treatment agent containing one or more selected from N-acylalanine, N-acyl-N-methyl- ⁇ -alanine, N-acylsarcosine, N-acylproline, N-acyl-N-methyltaurine, alkylbetaine, or a salt thereof.
  • the acyl group or alkyl group of compound (a''') preferably has a carbon chain length of C8 to C22.
  • the salt of compound (a''') is preferably a metal salt or a triethanolamine salt, more preferably a sodium salt, a potassium salt, or a triethanolamine salt. Another aspect of the present invention may be as follows.
  • a method for producing a surface-treated powder comprising: (i'') a step of treating a powder with a treatment liquid A''; and (ii'') a step of treating the powder with a treatment liquid B'',
  • the treatment solution A′′ contains (a′′′) one or more compounds selected from N-acylalanine, N-acyl-N-methyl- ⁇ -alanine, N-acylsarcosine, N-acylproline, N-acyl-N-methyltaurine, alkylbetaine, or salts thereof, and (e) water;
  • the treatment liquid B'' is an aqueous solution containing one or more components selected from metal ions and acids,
  • the method for producing the present invention wherein when component (f') contains a metal ion, the metal ion contains an ion of an alkaline earth metal or a zinc ion.
  • the treatment liquid A'' further contains (g) one or more compounds selected from amphoteric surfactants, nonionic surfactants, or salts thereof.
  • the compound (g) comprises one or more nonionic surfactants selected from polyoxyethylene condensation type, polyhydric alcohol ester type, and polyhydric alcohol condensation type.
  • the compound (g) comprises one or more amphoteric surfactants selected from amino acid type, betaine type, amine oxide type, or natural type amphoteric surfactants.
  • [70'] The method for producing a film according to any one of the above items [54'] to [69'], wherein the mixture obtained by mixing the treatment liquid A'' and the treatment liquid B'' forms a gel composition.
  • [71'] The method for producing a substrate according to any one of the above items [54'] to [70'], wherein the contact angle of the mixture obtained by mixing the treatment liquid A'' and the treatment liquid B'' is 90° or less.
  • [72'] The method for producing a film according to any one of the above items [54'] to [71'], wherein the mixture obtained by mixing the treatment liquid A'' and the treatment liquid B'' has a shear adhesive strength of 3000 Pa or more.
  • a powder surface treatment agent comprising treatment liquid A'' and treatment liquid B'', wherein treatment liquid A'' comprises: (a''') one or more compounds selected from N-acylalanine, N-acyl-N-methyl- ⁇ -alanine, N-acylsarcosine, N-acylproline, N-acyl-N-methyltaurine, alkylbetaine, or salts thereof; and (e) water; (f') the treatment liquid B'' is an aqueous solution containing one or more components selected from metal ions and acids, A powder surface treatment agent, wherein when the component (f') contains a metal ion, the metal ion contains an alkaline earth metal ion or a zinc ion.
  • [95'] The powder surface treatment agent according to any one of the above [76'] to [94'], wherein the mixture obtained by mixing the treatment liquid A'' and the treatment liquid B'' has a dynamic friction coefficient of 0.4 or more.
  • [96'] A surface-treated powder that has been surface-treated with the powder surface treatment agent according to any one of [76'] to [95'] above.
  • [97'] A cosmetic composition containing the powder described in [96'] above.
  • [99'] Use of the powder surface treatment agent according to any one of [76'] to [95'] above for producing a surface-treated powder having a contact angle of less than 90°.
  • a surface-treated powder whose surface is coated with a composition containing: (a''') one or more compounds selected from N-acylalanine, N-acyl-N-methyl- ⁇ -alanine, N-acylsarcosine, N-acylproline, N-acyl-N-methyltaurine, alkylbetaine, or a salt thereof; (e) water; and (f') one or more components selected from metal ions and acids, A surface-treated powder, wherein component (f') contains an alkaline earth metal ion, a zinc ion, or a citrate ion.
  • composition further comprises (b'') one or more compounds selected from fatty acids and salts thereof.
  • fatty acid of compound (b'') is a fatty acid having a carbon chain length of C8 to C22.
  • acyl component constituting compound (a'"') examples include acyl groups derived or derivable from linear or branched, saturated or unsaturated fatty acids having 8 to 22 carbon atoms, such as single fatty acid acyl groups such as octanoyl, caproyl, nonanoyl, caprinoyl, decanoyl, undecanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, arachidinoyl, behenoyl, palmitoleoyl, oleoyl, and linoleoyl, natural mixed fatty acid acyl groups such as coconut oil fatty acid acyl groups and hardened beef tallow fatty acid acyl groups, as well as aromatic carboxylic acid acyl groups such as benzoic acid acyl groups.
  • acyl groups derived or derivable from linear or branched, saturated or unsaturated fatty acids having 8 to 22 carbon atoms such as single
  • acyl groups can be derived from fatty acids, they can also be derived from raw materials other than fatty acids (fatty acid esters, fatty acid salts, acid halides, acid anhydrides, etc.).
  • the acyl moiety may be an acyl group having a carbon chain length of from C8 to C22, with an acyl group having a carbon chain length of from C8 to C20 being preferred, an acyl group having a carbon chain length of from C8 to C18 being more preferred, and an acyl group having a carbon chain length of from C8 to C14 being even more preferred.
  • the acyl group having a carbon chain length of C8 to C22 may be an octanoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, behenoyl group, palmitoleyl group, oleoyl group, linoleoyl group, or coconut oil fatty acid acyl group, of which an octanoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, palmitoleyl group, oleoyl group, linoleoyl group, or coconut oil fatty acid acyl group is preferred, an octanoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, or coconut oil fatty acid acyl group is more preferred, and an oct
  • the alkyl component constituting compound (a'"') is an alkyl group derived or derivable from a linear or branched, saturated or unsaturated fatty acid having 8 to 22 carbon atoms, such as octyl, capryl, nonyl, decyl, undecyl, dodecyl, tridecyl, myristyl, cetyl, stearyl, oleyl, linolyl, nonadecyl, arachidyl, eicosyl, behenyl, coconut oil alkyl group, etc.
  • the alkyl component may be an alkyl group having a carbon chain length of C8 to C22, preferably an alkyl group having a carbon chain length of C8 to C20, more preferably an alkyl group having a carbon chain length of C8 to C18, and even more preferably an alkyl group having a carbon chain length of C8 to C14.
  • the alkyl group having a carbon chain length of C8 to C22 may be an octyl group, a capryl group, a nonyl group, a decyl group, an undecyl group, a dodecyl group, a tridecyl group, a myristyl group, a cetyl group, a stearyl group, an oleyl group, a linolyl group, a nonadecyl group, an arachidyl group, an eicosyl group, a behenyl group, or a coconut oil alkyl group; [0049] Preferred are octyl, capryl, nonyl, decyl, undecyl, dodecyl, tridecyl, myristyl, cetyl, stearyl, oleyl, linolyl, and coconut alkyl groups, more preferred are octyl, capryl, nonyl, de
  • salts of compound (a'"') include pharmacologically acceptable salts, and examples thereof include alkali metal salts such as lithium salt, sodium salt, and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; and basic organic salts and triethanolamine salt.
  • alkali metal salts such as lithium salt, sodium salt, and potassium salt
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • ammonium salt and basic organic salts and triethanolamine salt.
  • sodium salt, potassium salt, ammonium salt, and triethanolamine salt are preferred, sodium salt, potassium salt, and triethanolamine salt are more preferred, and sodium salt is even more preferred.
  • polybasic acids such as dibasic acids, either monosalts (monosodium glutamate, etc.) or di-salts (disodium glutamate, etc.) can be used.
  • N-acylalanine and salts thereof constituting compound (a''') include octanoylalanine, the sodium salt of octanoylalanine, the potassium salt of octanoylalanine, the triethanolamine salt of octanoylalanine, decanoylalanine, the sodium salt of decanoylalanine, the potassium salt of decanoylalanine, the triethanolamine salt of decanoylalanine, lauroylalanine, the sodium salt of lauroylalanine, the potassium salt of lauroylalanine, the triethanolamine salt of lauroylalanine, myristoylalanine, the sodium salt of myristoylalanine, the potassium salt of myristoylalanine, the triethanolamine salt of myristoylalanine, palmitoylalanine, the sodium salt of palmitoylalanine, the potassium salt of palmitoylalanine, and the triethanolamine salt of palmitoylalanine
  • N-acylalanine and salts thereof include octanoylalanine, octanoylalanine sodium, octanoylalanine potassium, octanoylalanine triethanolamine, decanoylalanine, decanoylalanine sodium, decanoylalanine potassium, decanoylalanine triethanolamine, lauroylalanine, lauroylalanine sodium, lauroylalanine potassium, lauroylalanine triethanolamine, myristoylalanine, myristoylalanine sodium, myristoylalanine potassium, myristoylalanine triethanolamine, palmitoylalanine, palmitoylalanine sodium, palmitoylalanine potassium, palmitoylalanine triethanolamine, stearoylalanine, Preferred are sodium stearoylalanine, potassium stearoylalanine, triethanolamine oleoylalanine, sodium oleoylalanine, o
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include octanoylalanine, octanoylalanine sodium, octanoylalanine potassium, octanoylalanine ammonium, octanoylalanine triethanolamine, decanoylalanine, decanoylalanine sodium, decanoylalanine potassium, decanoylalanine ammonium, decanoylalanine triethanolamine, lauroylalanine, lauroylalanine sodium, lauroylalanine potassium, lauroylalanine ammonium, lauroylalanine triethanolamine, myristoylalanine, myristoylalanine sodium, myristoylalanine potassium, myristoylalanine ammonium salt, myristoylalanine triethanolamine, coconut oil fatty acid acylalanine, coconut oil fatty acid acylalanine Alternatively
  • N-acyl-N-methyl- ⁇ -alanine N-acylmethylalanine
  • salts thereof constituting compound (a''') include octanoylmethylalanine, the sodium salt of octanoylmethylalanine, the potassium salt of octanoylmethylalanine, the triethanolamine salt of octanoylmethylalanine, decanoylmethylalanine, the sodium salt of decanoylmethylalanine, the potassium salt of decanoylmethylalanine, the triethanolamine salt of decanoylmethylalanine, lauroylmethylalanine, the sodium salt of lauroylmethylalanine, the potassium salt of lauroylmethylalanine, the triethanolamine salt of lauroylmethylalanine, myristoylmethylalanine, the sodium salt of myristoylmethylalanine, the potassium salt of myristoylmethylalanine, the triethanolamine salt of myristoylmethyla
  • N-acylmethylalanine and salts thereof include octanoylmethylalanine, octanoylmethylalanine sodium, octanoylmethylalanine potassium, octanoylmethylalanine triethanolamine, decanoylmethylalanine, decanoylmethylalanine sodium, decanoylmethylalanine potassium, decanoylmethylalanine triethanolamine, lauroylmethylalanine, lauroylmethylalanine sodium, lauroylmethylalanine potassium, lauroylmethylalanine triethanolamine, myristoylmethylalanine, myristoylmethylalanine sodium, myristoylmethylalanine potassium, myristoylmethylalanine triethanolamine, palmitoylmethylalanine, palmitoylmethylalanine sodium, palmitoylmethylalanine potassium, palmitoylmethylalanine triethanolamine, stearoylmethylalanine, ste
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include octanoylmethylalanine, octanoylmethylalanine sodium, octanoylmethylalanine potassium, octanoylmethylalanine ammonium, octanoylmethylalanine triethanolamine, decanoylmethylalanine, decanoylmethylalanine sodium, decanoylmethylalanine potassium, decanoylmethylalanine ammonium, decanoylmethylalanine triethanolamine, lauroylmethylalanine, lauroylmethylalanine sodium, lauroylmethylalanine potassium, lauroylmethylalanine ammonium, lauroylmethylalanine triethanolamine, myristoylmethylalanine, myristoylmethylalanine sodium, myristoylmethylalanine potassium, myristoylmethylalanine triethanolamine
  • stearoyl sarcosine sodium salt of stearoyl sarcosine, potassium salt of stearoyl sarcosine, triethanolamine salt of stearoyl sarcosine, oleoyl sarcosine, sodium salt of oleoyl sarcosine, potassium salt of oleoyl sarcosine, triethanolamine salt of oleoyl sarcosine, linoleoyl sarcosine, sodium salt of linoleoyl sarcosine, potassium salt of linoleoyl sarcosine, triethanolamine salt of linoleoyl sarcosine, coconut oil fatty acid acyl sarcosine, sodium salt of coconut oil fatty acid acyl sarcosine, potassium salt of coconut oil fatty acid acyl sarcosine, and triethanolamine salt of coconut oil fatty acid
  • N-acyl sarcosine and salts thereof include octanoyl sarcosine, sodium octanoyl sarcosine, potassium octanoyl sarcosine, triethanolamine octanoyl sarcosine, decanoyl sarcosine, sodium decanoyl sarcosine, potassium decanoyl sarcosine, triethanolamine decanoyl sarcosine, lauroyl sarcosine, sodium lauroyl sarcosine, potassium lauroyl sarcosine, triethanolamine lauroyl sarcosine, myristoyl sarcosine, sodium myristoyl sarcosine, potassium myristoyl sarcosine, triethanolamine myristoyl sarcosine, palmitoyl sarcosine, sodium palmitoyl sarcos
  • octanoyl sarcosine sodium octanoyl sarcosine, potassium octanoyl sarcosine, triethanolamine octanoyl sarcosine, decanoyl sarcosine, sodium decanoyl sarcosine, potassium decanoyl sarcosine, triethanolamine decanoyl sarcosine, lauroyl sarcosine, sodium lauroyl sarcosine, potassium lauroyl sarcosine, triethanolamine lauroyl sarcosine, myristoyl sarcosine, sodium myristoyl sarcosine, potassium myristoyl sarcosine, triethanolamine myristoyl sarcosine, coconut oil fatty acid acyl sarcosine, sodium coconut oil fatty acid acyl sarcosine, potassium coconut oil fatty acid acy
  • N-acylamino acids and salts thereof having an acyl group with a carbon chain length of C8 to C22 include octanoyl sarcosine, sodium octanoyl sarcosine, potassium octanoyl sarcosine, ammonium octanoyl sarcosine, triethanolamine octanoyl sarcosine, decanoyl sarcosine, sodium decanoyl sarcosine, potassium decanoyl sarcosine, ammonium decanoyl sarcosine, triethanolamine decanoyl sarcosine, lauroyl sarcosine, sodium lauroyl sarcosine, potassium lauroyl sarcosine, ammonium lauroyl sarcosine, triethanolamine lauroyl sarcosine, myristoyl sarc
  • N-acylprolines and salts thereof constituting compound (a''') include octanoylproline, sodium salt of octanoylproline, potassium salt of octanoylproline, decanoylproline, sodium salt of decanoylproline, potassium salt of decanoylproline, lauroylproline, sodium salt of lauroylproline, potassium salt of lauroylproline, myristoylproline, sodium salt of myristoylproline, potassium salt of myristoylproline, palmitoylproline, sodium salt of palmitoylproline, and potassium salt of palmitoylproline.
  • Preferred N-acylprolines and salts thereof include octanoylproline, octanoylproline sodium, octanoylproline potassium, decanoylproline, decanoylproline sodium, decanoylproline potassium, lauroylproline, lauroylproline sodium, lauroylproline potassium, myristoylproline, myristoylproline sodium, myristoylproline potassium, palmitoylproline, palmitoylproline sodium, palmitoylproline potassium, stearoylproline, stearoylproline sodium, stearoylproline potassium, oleoylproline sodium, oleoylproline, oleoylproline potassium, linoleoylproline, linoleoylproline sodium, linoleoylproline potassium, coconut oil fatty acid acylproline, coconut oil fatty acid acy
  • octanoylproline More preferred are octanoylproline, octanoylproline sodium, octanoylproline potassium, decanoylproline, and decanoyl
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include octanoylproline, octanoylproline sodium, octanoylproline potassium, octanoylproline ammonium salt, octanoylproline triethanolamine, decanoylproline, decanoylproline sodium, decanoylproline potassium, decanoylproline ammonium salt, decanoylproline triethanolamine, lauroylproline, lauroylproline sodium, lauroylproline potassium, lauroylproline ammonium salt, lauroylproline triethanolamine, myristoylproline, myristoylproline sodium, myristoylproline potassium, and myristoylproline ammonium salt.
  • octanoylproline, sodium octanoylproline, potassium octanoylproline, decanoylproline, sodium decanoylproline, potassium decanoylproline, lauroylproline, sodium lauroylproline, potassium lauroylproline, sodium myristoylproline, potassium myristoylproline, coconut oil fatty acylproline, sodium coconut oil fatty acylproline, and potassium coconut oil fatty acylproline may be used.
  • N-acyl-N-methyltaurine N-acylmethyltaurine
  • salts thereof constituting compound (a'') include octanoylmethyltaurine, sodium salt of octanoylmethyltaurine, potassium salt of octanoylmethyltaurine, decanoylmethyltaurine, sodium salt of decanoylmethyltaurine, potassium salt of decanoylmethyltaurine, lauroylmethyltaurine, sodium salt of lauroylmethyltaurine, potassium salt of lauroylmethyltaurine, myristoylmethyltaurine, sodium salt of myristoylmethyltaurine, potassium salt of myristoylmethyltaurine, palmitoylmethyltaurine, sodium salt of palmitoylmethyltaurine, palmitoylmethyltaurine, Preferred are potassium salt of stearoyl methyl taurine, stearoyl methyl taurine, sodium salt of stearoyl methyl taurine, sodium salt
  • N-acylmethyltaurine and salts thereof include octanoylmethyltaurine, sodium octanoylmethyltaurine, potassium octanoylmethyltaurine, decanoylmethyltaurine, sodium decanoylmethyltaurine, potassium decanoylmethyltaurine, lauroylmethyltaurine, sodium lauroylmethyltaurine, potassium lauroylmethyltaurine, myristoylmethyltaurine, sodium myristoylmethyltaurine, potassium myristoylmethyltaurine, palmitoylmethyltaurine, sodium palmitoylmethyltaurine, potassium palmitoylmethyltaurine, stearoylmethyltaurine, Sodium stearoyl methyl taurate, potassium stearoyl methyl taurate, sodium oleoyl methyl taurate, oleoyl methyl taurine, potassium oleoyl methyl taurate, linoleoyl methyl
  • octanoyl methyl taurine sodium octanoyl methyl taurine, potassium octanoyl methyl taurine, decanoyl methyl taurine, sodium decanoyl methyl taurine, potassium decanoyl methyl taurine, lauroyl methyl taurine, sodium lauroyl methyl taurine, potassium lauroyl methyl taurine, myristoyl methyl taurine, sodium myristoyl methyl taurine, potassium myristoyl methyl taurine, coconut oil fatty acyl methyl taurine, sodium coconut oil fatty acyl methyl taurine, and potassium coconut oil fatty acyl methyl taurine.
  • N-acylamino acids having an acyl group with a carbon chain length of C8 to C22 and salts thereof include octanoyl methyl taurine, sodium octanoyl methyl taurine, potassium octanoyl methyl taurine, ammonium salt of octanoyl methyl taurine, triethanolamine octanoyl methyl taurine, decanoyl methyl taurine, sodium decanoyl methyl taurine, potassium decanoyl methyl taurine, ammonium salt of decanoyl methyl taurine, triethanolamine decanoyl methyl taurine, lauroyl methyl taurine, sodium lauroyl methyl taurine, potassium lauroyl methyl taurine, ammonium salt of lauroyl methyl taurine, triethanolamine lauroyl methyl taurine, myristoyl methyl taurine, sodium myristoyl methyl taurine, potassium myristoyl methyl taurine, ammonium salt of
  • alkyl betaines of compound (a'') include coco betaine, lauryl betaine, myristyl betaine, cetyl betaine, stearyl betaine, oleyl betaine, decyl betaine, and behenyl betaine. Coco betaine, lauryl betaine, and myristyl betaine are preferred, and coco betaine is more preferred. By using these alkyl betaines, it is possible to improve multiple properties of the treated powder, such as its hydrophilicity and pleasant feel.
  • compound (a''') preferably comprises N-acylalanine and/or N-acyl-N-methyl- ⁇ -alanine.
  • Compound (a''') is preferably N-acylalanine and/or N-acyl-N-methyl- ⁇ -alanine having an acyl group with a carbon chain length of C8 to C22.
  • salts of compound (a''') include pharmacologically acceptable salts, such as alkali metal salts such as lithium salt, sodium salt, and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; basic organic salts, and triethanolamine salt.
  • sodium salt, potassium salt, ammonium salt, and triethanolamine salt are preferred, sodium salt, potassium salt, and triethanolamine salt are more preferred, and sodium salt is even more preferred.
  • polybasic acids such as dibasic acids
  • both monosalts (monosodium glutamate, etc.) and di-salts (disodium glutamate, etc.) can be used.
  • the N-acyl amino acid of compound (a''') includes N-acylalanine and N-acyl-N-methyl- ⁇ -alanine
  • the total content of these amino acids in the surface treatment agent of this embodiment is preferably 5 to 40 mass%, and more preferably 10 to 30 mass%.
  • the concentration of compound (a'") in treatment liquid A” is preferably 5.0% by mass or more, more preferably 7.5% by mass or more, and even more preferably 10.0% by mass or more.
  • the concentration of compound (a'") in treatment liquid A” is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less.
  • the concentration of compound (a'") in treatment liquid A” may be preferably 5.0 to 40% by mass, more preferably 7.5 to 35% by mass, and even more preferably 10.0 to 30.0% by mass.
  • Treatment liquid B" is an aqueous solution containing (f') one or more components selected from metal ions and acids, and the metal ions of component (f') include alkaline earth metal ions or zinc ions, and are preferably alkaline earth metal ions or zinc ions.
  • the metal ions include magnesium ions, calcium ions, and zinc ions.
  • compounds that generate such ions include magnesium hydroxide, magnesium chloride, magnesium sulfate, magnesium nitrate, magnesium acetate, calcium hydroxide, calcium chloride, calcium sulfate, calcium nitrate, calcium acetate, zinc chloride, zinc nitrate, zinc sulfate, zinc acetate, and zinc hydroxide.
  • Component (f') preferably contains, as metal ions, ions of one or more metals selected from the group consisting of calcium, zinc, and magnesium, and more preferably contains, as metal ions, ions of one or more metals selected from calcium and magnesium.
  • the acid of component (f') include an aqueous solution of citric acid, an aqueous solution of tartaric acid, an aqueous solution of lactic acid, an aqueous solution of malic acid, an aqueous solution of succinic acid, an aqueous solution of ascorbic acid, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, and boric acid, and are preferably an aqueous solution of citric acid and an aqueous solution of sulfuric acid, and more preferably an aqueous solution of citric acid.
  • the predetermined concentration is, for example, a molar ratio relative to the metal ion (f') contained in treatment solution B" of 0.001 or more, 0.01 or more, 0.05 or more, etc. Furthermore, the predetermined concentration is, for example, a molar ratio relative to the compound (a''') contained in treatment solution A" of 0.01 or more, 0.05 or more, etc. If the component that inhibits salt formation is contained at such a concentration, the salt formation may be inhibited.
  • Treatment liquid A'' may further contain (g) one or more compounds selected from amphoteric surfactants, nonionic surfactants, or salts thereof.
  • amphoteric surfactant of the compound (g) include amino acid amphoteric surfactants such as sodium cocoamphoacetate, sodium lauroamphoacetate, disodium cocoamphodiacetate, sodium cocoamphopropionate, and sodium palmamphoacetate; sulfobetaine types such as lauramidopropyl hydroxysultaine, lauryl hydroxysultaine, and cocamidopropyl hydroxysultaine; phosphobetaine types such as lauryl hydroxyphosphobetaine; alkylamidobetaine types such as cocamidopropyl betaine, lauramidopropyl betaine, myristamidopropyl betaine, pearl nucleus fatty acid amidopropyl betaine, (capryl/capramido)propyl betaine, and undecylenamidopropyl betaine;
  • amphoteric surfactant of compound (g) is preferably one or more of the following: amino acid amphoteric surfactants, betaine amphoteric surfactants, amine oxide amphoteric surfactants, and natural amphoteric surfactants; more preferably one or more of the following: betaine amphoteric surfactants or natural amphoteric surfactants; even more preferably one or more of the following: lecithins; and particularly preferably hydrogenated lecithin.
  • the nonionic surfactants of compound (g) include steareth-2, steareth-3, steareth-8, steareth-10, steareth-11, steareth-15, steareth-20, steareth-21, ceteareth-12, ceteareth-20, ceteareth-25, ceteth-3, ceteth-6, ceteth-10, ceteth-15, ceteth-20, ceteth-25, ceteth-30, trideceth-6, trideceth ...
  • Deceth-9 Trideceth-10, Trideceth-12, Beheneth-5, Beheneth-10, Beheneth-20, Beheneth-30, Laureth-2, Laureth-3, Laureth-4, Laureth-7, Laureth-9, Laureth-21, Laureth-23, Laureth-25, Laureth-30, Isosteareth-20, Isoceteth-10, Isoceteth-20, Isoceteth-25, Octyldodeceth-16, Octyldodeceth-17, Octyldodeceth-29, Octyldodeceth-30, Octyldodeceth-40, Octyldodeceth-50, Octyldodeceth-60, Octyldodeceth-70, Octyldodeceth-80, Octyldodeceth-90, Octyldodeceth-10, Octyldodeceth-20, Octyldodeceth-25, Octy
  • Polyoxyethylene polyoxypropylene alkyl ethers such as butyltetradeceth-30, polyoxyethylene fatty acid esters such as PEG-6 isostearate, PEG-8 isostearate, PEG-10 isostearate, PEG-12 isostearate, PEG-2 laurate, PEG-4 laurate, PEG-12 laurate, PEG-2 stearate, PEG-10 stearate, PEG-20 stearate, PEG-25 stearate, PEG-40 stearate, PEG-45 stearate, PEG-55 stearate, PEG-75 stearate, PEG-100 stearate, PEG-150 stearate, and PEG-150 distearate, PEG-3 glyceryl isostearate, PEG-5 glyceryl isostearate, and PEG-6 glyceryl isostearate.
  • polyoxyethylene fatty acid esters such as PEG-6 isostearate, PEG-8 isostearate, PEG
  • Polyoxyethylene polyhydric alcohol fatty acid esters such as PEG-8 glyceryl isostearate, PEG-15 glyceryl isostearate, PEG-20 glyceryl isostearate, PEG-25 glyceryl isostearate, PEG-30 glyceryl isostearate, PEG-60 glyceryl isostearate, PEG-5 glyceryl triisostearate, PEG-10 glyceryl triisostearate, PEG-20 glyceryl triisostearate, polyglyceryl-3 diisostearate, polyglyceryl-10 diisostearate, PEG-7 glyceryl coconut oil fatty acid, PEG-5 glyceryl stearate, PEG-15 glyceryl stearate, sorbeth-30 tetraoleate, sorbeth-40 tetraoleate, and sorbeth-60 tetraoleate, PEG- Polyoxyethylene hydrogenated castor oils such as PEG-10
  • the nonionic surfactant of compound (g) is preferably one or more of the polyoxyethylene condensation type, polyhydric alcohol condensation type, or polyhydric alcohol ester type, more preferably one or more of the polyoxyethylene condensation type or polyhydric alcohol condensation type, even more preferably one or more of the polyoxyethylene alkyl ethers or polyglyceryl fatty acid esters, and particularly preferably one or more of the following: Beheneth-20, PEG-20 hydrogenated castor oil, or Polyglyceryl laurate-10.
  • the concentration of compound (g) in treatment liquid A" is 0% by mass or more, more preferably 0.01% by mass or more, even more preferably 0.10% by mass or more, particularly preferably 0.25% by mass or more, and most preferably 0.50% by mass or more.
  • the concentration of compound (g) in treatment liquid A" is preferably 40% by mass or less, more preferably 10% by mass or less, even more preferably 5.0% by mass or less, and particularly preferably 2.0% by mass or less.
  • the concentration of compound (g) in treatment liquid A" may be preferably 0.01 to 40% by mass, more preferably 0.1 to 10% by mass, even more preferably 0.25 to 5.0% by mass, and particularly preferably 0.50 to 2.0% by mass.
  • treatment solution A'' may contain compound (b'') one or more compounds selected from fatty acids and salts thereof, and when fatty acids and salts thereof are contained, they are preferably fatty acids and salts thereof having a carbon chain length of C8 to C22.
  • the fatty acid that is compound (b") may be a straight-chain fatty acid or a branched-chain fatty acid, with straight-chain fatty acids being preferred. It may be a saturated fatty acid or an unsaturated fatty acid, with saturated fatty acids being preferred.
  • the fatty acid may be a fatty acid having a carbon chain length of C8 to C22, with fatty acids having a carbon chain length of C8 to C20 being preferred, fatty acids having a carbon chain length of C8 to C18 being more preferred, and fatty acids having a carbon chain length of C8 to C14 being even more preferred.
  • fatty acids having a carbon chain length of C8 to C22 include octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, eicosenoic acid, erucic acid, hardened beef tallow fatty acid, coconut oil fatty acid, and palm oil fatty acid.
  • Fatty acids having a carbon chain length of C8 to C22 are preferably octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidic acid, oleic acid, and coconut oil fatty acid; more preferably octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, and coconut oil fatty acid; and even more preferably octanoic acid, decanoic acid, lauric acid, myristic acid, and coconut oil fatty acid.
  • salts of fatty acids having a carbon chain length of C8 to C22 include pharmacologically acceptable salts, such as alkali metal salts (e.g., lithium salts, sodium salts, and potassium salts); alkaline earth metal salts (e.g., calcium salts and magnesium salts); ammonium salts; basic organic salts; and triethanolamine salts.
  • alkali metal salts e.g., lithium salts, sodium salts, and potassium salts
  • alkaline earth metal salts e.g., calcium salts and magnesium salts
  • ammonium salts e.g., sodium salts, potassium salts, ammonium salts, and triethanolamine salts are preferred from the viewpoint of solubility; sodium salts and potassium salts are more preferred, and sodium salts are even more preferred.
  • the concentration of compound (b") in treatment liquid A” is 0.0% by mass or more, preferably 0.5% by mass or more, and more preferably 1.0% by mass or more.
  • the concentration of compound (b") in treatment liquid A” is preferably 20% by mass or less, more preferably 10% by mass or less, and even more preferably 5% by mass or less.
  • the concentration of compound (b") in treatment liquid A” may be preferably 0.5 to 20% by mass, more preferably 0.5 to 10% by mass, and even more preferably 1.0 to 5% by mass.
  • Compound (b'') in treatment solution A' may be added to treatment solution A'' as a raw material separately from the other components in treatment solution A'', or may be added to treatment solution A'' as a component contained in a raw material corresponding to the other components in treatment solution A'' (e.g., compound (a''')).
  • Treatment solution A" preferably has a pH of 7.0 or higher, more preferably 8.0 or higher, and even more preferably 8.5 or higher.
  • Treatment solution A" preferably has a pH of 13.0 or lower, more preferably 11.5 or lower.
  • citric acid aqueous solution tartaric acid aqueous solution, lactic acid, malic acid aqueous solution, succinic acid aqueous solution, ascorbic acid aqueous solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, potassium hydroxide, arginine, lysine, etc.
  • citric acid aqueous solution tartaric acid aqueous solution, lactic acid, malic acid aqueous solution, succinic acid aqueous solution, ascorbic acid aqueous solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, potassium hydroxide, arginine, lys
  • a pH adjuster is used that does not inhibit the salt formation between compound (a''') in treatment solution A" and the metal ions of component (f') in treatment solution B". More preferably, a pH adjuster is used that does not chelate the metal ions of component (f') in treatment solution B'. Lactic acid, ascorbic acid aqueous solution, acetic acid, sulfuric acid, hydrochloric acid, phosphoric acid, boric acid, sodium hydroxide, potassium hydroxide, arginine, or lysine is even more preferred, with sodium hydroxide, potassium hydroxide, and arginine being particularly preferred.
  • the powder used in the surface treatment method of the present invention is not particularly limited as long as it is used for industrial purposes or cosmetics (pigments, coloring matters, resins, pearls), and examples thereof include resin powders such as nylon powder, nylon beads, silicone beads, and polyethylene beads; Metal oxides such as iron oxide (yellow pigment), iron oxide (red pigment), iron oxide (black pigment), tin oxide, chromium oxide, cobalt oxide, zinc oxide, pigment-grade zinc oxide, titanium oxide, pigment-grade titanium oxide, zirconium oxide, aluminum oxide, cerium oxide, fine particle titanium oxide, ultrafine particle titanium oxide, fine particle zinc oxide, and fine particle iron oxide; silicon-containing powders such as silicates (silicate (Al/Ca/Na), silicate (Na/Mg)), sericite, mica, talc, kaolin, bentonite, aluminum silicate, magnesium silicate, cubic sodium aluminosilicate, silicon carbide, hydrous silica, and silicon oxides such as silicic anhydride (lea
  • the powder may be surface-treated with silicone, fluorine compound, silane coupling agent, silane, organic titanate, fatty acid, metal soap, oil, amino acid, or the like.
  • Crystalline or amorphous powders such as resin powders, silicon-containing powders, metal oxides, carbon-containing powders, fluorine-containing powders, metal salts, boron-containing powders, and composite powders are preferred in terms of improving water repellency and oil repellency after treatment.
  • the powder may preferably be, for example, talc, mica, sericite, titanium oxide, red iron oxide, yellow iron oxide, black iron oxide, pearl powder, colored pearl pigment.
  • treatment liquid A" is used in an amount of 0.5 parts by mass or more, preferably 1.0 parts by mass or more, more preferably 2.0 parts by mass or more, even more preferably 4.0 parts by mass or more, and particularly preferably 8.0 parts by mass or more, relative to 100 parts by mass of powder.
  • Treatment liquid A” is used in an amount of 1000 parts by mass or less, preferably 100 parts by mass or less, more preferably 50.0 parts by mass or less, even more preferably 40.0 parts by mass or less, and particularly preferably 30 parts by mass or less, relative to 100 parts by mass of powder.
  • the mixture obtained by mixing treatment liquid A” and treatment liquid B” forms a gel-like composition, which can improve several properties of the treated powder selected from hydrophilicity, a pleasant feel, and the like.
  • the mixture obtained by mixing treatment liquid A” and treatment liquid B” forms a smooth gel-like composition on the surface of the powder, making it possible to produce treated powder whose surface is coated with a smooth gel-like composition.
  • the dynamic friction coefficient of the mixture obtained by mixing treatment liquid A” and treatment liquid B” is preferably 0.4 to 2.0, more preferably 0.4 to 1.5, and even more preferably 0.4 to 1.0.
  • the dynamic friction coefficient can be measured as an average dynamic friction coefficient using a Tribomaster (manufactured by Trinity Labs, product name: TL201Ts).
  • the aqueous cosmetic may be a cosmetic whose solvent is water.
  • the aqueous cosmetic may also be a cosmetic containing 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more of water.
  • the contact angle was measured by sprinkling the prepared surface treatment composition mixture powder on a 1.5 x 6 cm square double-sided tape (manufactured by Daikyosha, B-115 type) attached to a slide glass, shaking off excess powder, and then measuring the contact angle with water at 2.0 ⁇ m using a fully automatic contact angle measuring device (manufactured by Kyowa Interface Science Co., Ltd., DMo-702). L was dropped onto the surface, and the contact angle of water was measured after 10 seconds.
  • the mixture obtained by mixing treatment liquid A" and treatment liquid B" preferably has a shear adhesive strength of 3000 Pa or more, more preferably 3200 Pa or more, and even more preferably 3400 Pa or more.
  • a powder with an excellent moist feel can be prepared when processed into a powder.
  • the shear adhesive strength can be measured using a dynamic viscoelasticity measuring device (Discovery HR 20 manufactured by TA Instruments) equipped with a powder rheology accessory manufactured by the same company, in accordance with JIS [Z885:2016].
  • the powder obtained by the method for producing a surface-treated powder of the present invention or the powder surface-treated with the treatment agent of the present invention can also be said to be a powder whose surface is coated with a composition containing compound (a'"), (e) water, and component (f').
  • the composition may further contain compound (g) and/or (b'').
  • the acyl or alkyl group of (a''') preferably has a carbon chain length of C8 to C22.
  • (a''') preferably includes N-acylalanine and/or N-acyl-N-methyl- ⁇ -alanine.
  • the powder obtained by the method for producing a surface-treated powder of the present invention, the powder surface-treated with the treatment agent of the present invention, or the surface-coated powder is excellent in multiple properties selected from among hydrophilicity and a pleasant feel. Furthermore, by using the powder obtained by the method for producing a surface-treated powder of the present invention in a cosmetic composition, the stability and SPF value of the composition may be improved.
  • the contact angle of the surface-treated powder is preferably reduced by 30% or more, more preferably by 40% or more, and even more preferably by 50% or more, compared to the corresponding untreated powder. Furthermore, when the corresponding untreated powder is hydrophilic, the contact angle is preferably reduced by 30% or more, more preferably by 40% or more, compared to the corresponding untreated powder.
  • the contact angle is preferably reduced by 70% or more, more preferably by 80% or more, compared to the corresponding untreated powder.
  • the contact angle of the corresponding untreated powder is less than 90°, and when the corresponding untreated powder is hydrophobic, the contact angle of the corresponding untreated powder is 90° or more.
  • the composition that coats the surface of the powder forms a smooth gel-like composition on the surface of the powder, thereby producing a treated powder coated with a smooth gel-like composition.
  • the dynamic friction coefficient of the composition is preferably 0.4 to 2.0, more preferably 0.4 to 1.5, and even more preferably 0.4 to 1.0.
  • the dynamic friction coefficient can be measured as an average dynamic friction coefficient using a Tribomaster (manufactured by Trinity Labs, product name: TL201Ts). Specifically, the dried mixture was sprinkled on double-sided tape attached to a glass slide, and excess powder was shaken off. Then, a tactile contactor (manufactured by Trinity Labs, product name: finger model fingerprint type) was used to measure the dynamic friction coefficient using a Tribomaster (manufactured by Trinity Labs, product name: TL201Ts). The measurement conditions for the friction tester were a load of 50 gf, a test table movement speed of 25 mm/sec, and a measurement distance of 25 mm.
  • the contact angle of the composition is 90° or less, more preferably 50° or less, and even more preferably 30° or less. Having the contact angle within the above range makes it possible to prepare a powder with excellent hydrophilicity when processed into a powder.
  • the contact angle of the composition can be measured by sprinkling the prepared surface treatment composition mixture powder on a 1.5 x 6 cm square double-sided tape (manufactured by Daikyo Co., Ltd., B-115 model) attached to a glass slide, shaking off excess powder, and then depositing 2.0 ⁇ L of water using a fully automatic contact angle measuring device (manufactured by Kyowa Interface Science Co., Ltd., DMo-702). The contact angle of water after 10 seconds can be measured.
  • the shear adhesive strength of the composition is 3000 Pa or more, more preferably 3200 Pa or more, and even more preferably 3400 Pa or more.
  • a powder with an excellent moist feel can be prepared when processed into a powder.
  • the shear adhesion can be measured using a dynamic viscoelasticity measuring device (Discovery HR 20, manufactured by TA Instruments) equipped with a powder rheology accessory manufactured by the same company, in accordance with JIS [Z885:2016]. It was confirmed that the shear adhesion of the surface-treated powder coated with the composition was increased synergistically by combining two or more components in treatment liquid A". The synergistic increase in shear adhesion confirmed that a powder with an excellent moist feel could be prepared.
  • Cosmetic compositions containing powders surface-treated by the method for producing surface-treated powders of the present invention, or cosmetic compositions containing powders surface-treated with the treating agent of the present invention, or the surface-coated powders can be made into any form of cosmetic that can be applied to desired areas (e.g., skin, hair, scalp, lips, eyes, eyelashes, eyelids, nails) using conventional methods.
  • cosmetic compositions for skin, lips, eyelashes, and nails include sunscreens such as sunscreens, body powders, and sprays; makeup cosmetics such as foundations, primers, body colors, bronzers, face powders, nail polishes, cheek colors, makeup bases, and concealers; lip cosmetics such as lip colors, lip liners, and lipsticks; eye makeup cosmetics such as eyeliners, eye shadows, eyebrow makeup, and mascara; leave-on cosmetics such as emulsions, lotions, creams, gels, and serums; and face masks.
  • cosmetic compositions for hair include hair styling products, hair emulsions, hair treatments, hair conditioners, and hair lotions.
  • cosmetics for the scalp include hair growth agents.
  • Preferred cosmetics include makeup cosmetics, eye makeup cosmetics, lip cosmetics, and leave-on cosmetics.
  • Preferred topical preparations include ointments, creams, mousses, and gels.
  • the cosmetic raw material composition of this embodiment can be used in combination with various base materials depending on the application and purpose, as long as the object of the present invention is not impaired.
  • dispersants include natural gums such as gum arabic and gum tragacanth, glucosides such as saponin, cellulose derivatives such as methyl cellulose, carboxy cellulose and hydroxymethyl cellulose, natural polymers such as lignin sulfonates and shellac, anionic polymers such as polyaspartates, polyacrylates, salts of styrene-acrylic acid copolymers, salts of vinylnaphthalene-maleic acid copolymers, sodium salts of ⁇ -naphthalenesulfonic acid formalin condensates, and phosphates, and nonionic polymers such as polyvinyl alcohol, polyvinylpyrrolidone and polyethylene glycol;
  • the acyl group is an acyl group derived or derivable from a linear or branched, saturated or unsaturated fatty acid with 8 to 22 carbon atoms, such as octanoyl, caproyl, nonanoyl, caprinoyl, decanoyl, undecanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, arachidinoyl, behenoyl, palmitoleoyl, oleoyl, or linoleoyl groups; natural mixed fatty acid acyl groups such as coconut oil fatty acid acyl and hydrogenated beef tallow fatty acid acyl; and aromatic carboxylic acid acyl groups such as benzoic acid acyl.
  • acyl groups can be derived from fatty acids, they can also be derived from raw materials other than fatty acids (fatty acid esters, fatty acid salts, acid halides, acid anhydrides, etc.).
  • the constituent amino acids include the above-mentioned acidic amino acids such as aspartic acid, or amino acids such as alanine, valine, leucine, isoleucine, proline, methionine, cysteine, tryptophan, tyrosine, phenylalanine, asparagine, glutamine, serine, threonine, oxyproline, ⁇ -aminopropionic acid, ⁇ -aminobutyric acid, anthranilic acid, m-aminobenzoic acid, and p-aminobenzoic acid, or salts thereof, alkyl ether carboxylates, amide ether carboxylates, alkyl sulfates (AS), polyoxyethylene alkyl ether sulfates (A
  • Hydrocarbons such as paraffin, liquid paraffin, heavy liquid paraffin, light liquid paraffin, petrolatum, ceresin, microcrystalline wax, isoparaffin, ozokerite, squalene, pristane, squalane, isododecane, and isohexadodecane; waxes such as beeswax, spermaceti, lanolin, carnauba wax, candelilla wax, cotton wax, bayberry wax, ivory wax, montan wax, rice bran wax, koji wax, lanolin acetate, liquid lanolin, sugarcane wax, isopropyl lanolinate, hexyl laurate, hydrogenated jojoba oil, reduced lanolin, jojoba wax, hard lanolin, shellac wax, polyoxyethylene cholesterol ether, polyoxyethylene lanolin alcohol ether, polyoxyethylene lanolin alcohol acetate, lanolin fatty acid polyethylene glycol, polyoxyethylene hydrogenated lanolin alcohol ether
  • Higher fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, behenic acid, undecylenic acid, 12-hydroxystearic acid, palmitoleic acid, oleic acid, lanolin fatty acids, hard lanolin fatty acids, soft lanolin fatty acids, linoleic acid, linolenic acid, erucic acid, docosahexaenoic acid, eicosapentaenoic acid, isohexadecanoic acid, anteisohenicosanoic acid, 12-hydroxystearic acid, long-chain branched fatty acids, dimer acids, hydrogenated dimer acids, and their aluminum salts, calcium salts, magnesium salts, zinc salts, potassium salts, and other metal soaps, as well as nitrogen-containing derivatives such as amides; lauryl alcohol Higher alcohols such as hexyldecanol, octyld
  • Volatile and non-volatile silicones such as dimethylpolysiloxane, polyether-modified silicone, alcohol-modified silicone, methylphenylpolysiloxane, epoxy-modified silicone, fluorine-modified silicone, alkyl-modified silicone, alkoxy-modified silicone, amino-modified silicone, polymeric silicone, volatile silicone, and cyclic silicone; polyols such as glycerin, diglycerin, polyglycerin, 1,3-butanediol, propanediol, and polyethylene glycol;
  • Moisturizing agents such as alkylglycines (e.g., N-methylglycine, N,N-dimethylglycine, N,N,N-trimethylglycine, N-ethylglycine, glycylbetaine), sorbitol, raffinose, pyrrolidone carboxylates, lactates, hyaluronates, ceramides, (poly)saccharides (e.g., trehalose, xylobiose, maltose, sucrose, glucose, and plant mucilage polysaccharides) and their derivatives, glycosaminoglycans (e.g., water-soluble chitin, chitosan, pectin, and chondroitin sulfate and their salts), amino acids (e.g., glycine, serine, threonine, alanine, aspartic acid, tyrosine, valine
  • Water- and oil-soluble polymers such as hydroxyethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyltrimethylammonium chloride ether, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, methylhydroxypropyl cellulose, soluble starch, carboxymethyl starch, methyl starch, propylene alginate, glycol esters, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, carboxyvinyl polymers, polyacrylates, guar gum, locust bean gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, xanthan gum, dextran, succinoglucan, curdlan, hyaluronic acid, gelatin, casein, albumin, collagen, methoxyethylene maleic anhydride copolymer, amphoteric methacrylate copolymer, polydimethylm
  • Thickening and foam-increasing ingredients such as cationic cellulose derivatives, cationic starch, cationic guar gum derivatives, diallyl quaternary ammonium salt/acrylamide copolymers, quaternized polyvinylpyrrolidone derivatives, quaternized vinylpyrrolidone/vinylimidazole polymers, polyglycol/amine condensates, quaternized collagen polypeptides, polyethyleneimine, cationic silicone polymers, adipic acid/dimethylaminohydroxypropyldiethylenetriamine copolymers, polyaminopolyamides, cationic chitin derivatives, cationic polymers such as quaternized polymers, polyethylene glycol fatty acid esters, polyoxyethylene fatty acid ester methylglycosides, and tetradecene sulfonates;
  • Oil gelling agents such as dextrin fatty acid esters, glycerin fatty acid esters, and hydroxystearic acid; sequestering agents such as ethylenediaminetetraacetic acid and its salts, hydroxyethylenediaminetriacetic acid and its salts, phosphoric acid, ascorbic acid, succinic acid, gluconic acid, polyphosphates, metaphosphates, and hinokitils;
  • Antiseptics and antibacterial agents such as parahydroxybenzoic acid esters, benzoic acid and its salts, phenoxyethanol, hinokitiol, salicylic acid and its salts, sorbic acid and its salts, dehydroacetic acid and its salts, parachlormetacresol, hexachlorophene, boric acid, resorcinol, tribromosalan, o-phenylphenol, thiram, photosensitizer No.
  • pH adjusters such as citric acid, malic acid, adipic acid, glutamic acid, and aspartic acid
  • anti-dandruff and itch-reducing agents such as trichlorocarbanilide, salicylic acid, zinc pyrithione, isopropyl methyl, and phenol.
  • Benzoic acid-based UV absorbers such as para-aminobenzoic acid, para-aminobenzoic acid monoglycerin ester, N,N-dipropoxypara-aminobenzoic acid ethyl ester, N,N-diethoxypara-aminobenzoic acid ethyl ester, N,N-dimethylpara-aminobenzoic acid ethyl ester, N,N-dimethylpara-aminobenzoic acid butyl ester, and N,N-dimethylpara-aminobenzoic acid ethyl ester; anthranilic acid-based UV absorbers such as homomenthyl-N-acetylanthranilate; salicylic acid-based UV absorbers such as salicylic acid and its sodium salt, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzy
  • Ascorbic acid and its salts alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, magnesium salt, calcium salt, as well as ammonium salt, amino acid salt, etc.
  • ascorbic acid derivatives L-ascorbic acid alkyl ester, L-ascorbic acid phosphate ester and its salt, L-ascorbic acid-2-sulfate ester and its salt, L-ascorbic acid glucoside, etc.
  • alkoxysalicylic acid and its salt alkoxy groups include, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, etc.), hydroquinone glycosides and their derivatives (arbutin, etc.), kojic acid and its derivatives, ellagic acid, chamomile extract, althea extract, licorice extract, mulberry bark extract, raspberry extract, apple flavonoids, bran extract, vitamin E and its derivatives, hin
  • Circulation promoters such as Swertia japonica extract, cepharanthine, vitamin E and its derivatives, and gamma oryzanol; topical stimulants such as capsicum tincture, angelica rhododendron tincture, cantharides tincture, and nicotinic acid benzyl ester; nutrients such as various vitamins and amino acids; female hormones; hair root activators;
  • Anti-inflammatory agents such as ricyrrhizinic acid, glycyrrhizinic acid derivatives, allantoin, azulene, aminocaproic acid, and hydrocortisone; astringents such as zinc oxide, zinc sulfate, allantoin hydroxyaluminum, aluminum chloride, aluminum sulfate, zinc sulfocarbonate, tannic acid, citric acid, and lactic acid; cooling agents such as menthol and camphor; antihistamines such as diphenhydramine hydrochloride, chlorpheniramine maleate, and glycyrrhizinic acid derivatives;
  • Antioxidants such as tocopherols, BHA, BHT, gallic acid, and NDGA; sebum suppressants such as estradiol, estrone, and ethinyl estradiol; exfoliants and dissolvers such as sulfur, salicylic acid, and resorcinol; alpha-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid; and beta-hydroxy acids such as salicylic acid.
  • sebum suppressants such as estradiol, estrone, and ethinyl estradiol
  • exfoliants and dissolvers such as sulfur, salicylic acid, and resorcinol
  • alpha-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid
  • beta-hydroxy acids such as salicylic acid.
  • Test Example 1 Preparation of composition and storage stability test at low temperature (preparation of composition) Each composition prepared by mixing and dissolving the components (a), (b), (c), (d), and (e) shown in Table 1 and other components at the concentrations shown in Table 1 was used for the following evaluations.
  • the composition was filled into a 20 mL transparent glass bottle, capped, and left to stand at ⁇ 5°C, 0°C, and 25°C, respectively. After storage for 1 month and 3 months, the bottle was removed from storage and left to stand for about 3 hours, and then returned to room temperature, after which the state of solution was visually confirmed. The state of solution (homogeneity (presence or absence of separation), presence or absence of precipitates or floating matter) was visually judged based on the following criteria. (Judgment criteria) D: Clear precipitates or floating matter are observed.
  • C Precipitates or floating matter are observed, covering the bottom or the liquid surface thinly.
  • B Precipitates or floating matter are observed scattered on the bottom or the liquid surface.
  • A Precipitates or floating matter are observed, but when stirred at room temperature, they dissolve and become a translucent solution.
  • S A translucent solution with no precipitates or floating matter.
  • SS A transparent solution with no precipitates or floating matter.
  • compositions were filled into 20 mL transparent glass bottles, capped, and left to stand at 50°C. After storage for 3 months, the bottles were removed from storage and left to stand for about 3 hours, and then returned to room temperature, after which the state of solution was evaluated visually.
  • the transmittance at 430 nm was measured and evaluated based on the following criteria. (Judgment criteria) D. Precipitates or floating matter are observed. C. Precipitates or floating matter are observed, covering the bottom or the liquid surface thinly. B. Precipitates or floating matter are observed scattered on the bottom or the liquid surface. A.
  • the solution is translucent, and no precipitates or floating matter are observed.
  • S. The solution is transparent, with no precipitates or floating matter and a transmittance of 90% or more but less than 94%.
  • SS. The solution is transparent, with no precipitates or floating matter and a transmittance of 94% or more.
  • Test Example 2 Evaluation of the antifungal effect of surface treatment composition A (preparation of composition) Each composition prepared by mixing and dissolving the components (a), (b), (c), (d), and (e) shown in Table 2 and other components at the concentrations shown in Table 2 was used for the following evaluations.
  • test strain A. b Aspergillus brasiliensis (Aspergillus niger) NBRC 9455 2.
  • Preparation of test bacterial solution The test bacterial solution was prepared by pre-cultivating the bacteria on Sabouraud glucose agar medium at 22.5°C for 6 to 10 days. The pre-cultured bacteria were scraped with a platinum loop and suspended in sterilized saline containing 0.05% polysorbate 80, and the concentration was adjusted to approximately 10 cells/mL. 3.
  • SS A decrease of 1.5 Log or more by day 7, a decrease of 2.5 Log or more by day 14, and death by day 21.S: Other than SS, death by day 21.A: Death by day 28.B: Not killed by day 28, but a decrease of 4 Log or more.C: Not killed by day 28, but a decrease of 3 Log or more.D: Even on day 28, the decrease in the number of live bacteria is 2 Log or less.E: Even on day 28, the decrease in the number of live bacteria is 1 Log or less.
  • Reference Examples 1 and 2 which contain arginine, showed a high antifungal effect.
  • Reference Example 4 which does not contain compound (a) or compound (b), even when it contains arginine, showed no antifungal effect.
  • the arginine content was 0.75% by mass or less (Reference Example 3), no antifungal effect was observed.
  • Test Example 3 Evaluation of physical properties and functionality of powder composition (preparation of powder composition) Each of the various untreated powder components shown in Tables 3-1 and 3-2 was weighed and stirred in a 75 mL mill and mixer (TML162, manufactured by Tescom Co., Ltd.), and then surface treatment composition A or its comparative composition was added and mixed. Thereafter, surface treatment composition B or its comparative composition shown in Tables 3-1 and 3-2 was added and mixed to obtain each powder composition.
  • TML162 mill and mixer
  • Test Example 4 Evaluation of moisturizing properties of emulsion formulations containing powder compositions.
  • a constant temperature and humidity chamber 23°C, 40% relative humidity (RH)
  • subjects were rinsed with 3 L of water at 35°C and allowed to acclimate for 30 minutes.
  • the moisture content of the stratum corneum on the flexor side of the forearm was measured as the skin capacitance value using a Corneometer CM 825 (Courage+Khazaka Co., Ltd.), and the initial value was recorded.
  • Comparative Example 16 a high viable cell count was maintained even after 28 days, and the antiseptic effect against mold was poor. Furthermore, when surface treatment compositions A or B were used alone, a high viable bacterial count was maintained after 28 days even at high dosages, but the powders to which both surface treatment compositions A and B were applied (Examples 44 to 46) showed good antifungal effects, and a synergistic effect was observed when the compositions were combined (Table 8 and Figure 1).
  • Test Example 8 Preparation of gel compositions of surface treatment compositions A and B and evaluation of their physical properties (preparation of compositions)
  • Surface treatment composition A and its comparative composition shown in Table 9 were prepared in the same manner as in Test Example 1 (preparation of compositions), and weighed into glass vials in the amounts shown in Table 10.
  • surface treatment composition B was added in the amount shown in Table 10, and the mixture was stirred to obtain gel compositions.
  • the gel compositions shown in Table 10 were allowed to stand at constant temperature and humidity (23°C, 40% relative humidity (RH)) for one day or more, and the amount of moisture when the change in mass reached equilibrium was measured using a Karl Fischer moisture meter.
  • the moisture amount at constant temperature and humidity relative to the initial moisture amount of the gel composition was calculated as the moisture retention amount (%) of the gel composition (a powder treatment agent obtained by mixing surface treatment composition A and surface treatment composition B).
  • the amount of water relative to the total mass of compounds (a) and (b) contained in the composition under constant temperature and humidity was calculated and defined as the amount of water retained relative to the total mass of compounds (a) and (b).
  • Reference Examples 19 to 23 which used the surface treatment compositions of Examples 47 and 48 containing (c) a polyhydric alcohol, smooth gels were formed, and as shown in Table 10, the measured average dynamic friction coefficients were 3.3 to 4.4.
  • Reference Examples 24 and 25 which used Comparative Example 17 containing no (c) polyhydric alcohol, gels with a strong squeaky feeling were obtained, and the average dynamic friction coefficients were low, showing values of 0.6 or less.
  • the compositions of Reference Examples 24 and 25 were confirmed to be in the form of white powder rather than gel at the time of measurement.
  • the water retention amounts were 15 to 23% in Reference Examples 19 to 23, while low values of 7% or less were shown in Reference Examples 24 and 25.
  • Reference Examples 19 to 23, which contained (c) a polyhydric alcohol showed higher values than Reference Examples 24 and 25.
  • Test Example 9 Measurement of water retention of powder composition (preparation of powder composition) Treated powder compositions of Examples and Comparative Examples listed in Table 11 were obtained in the same manner as in the preparation of the powder composition of Test Example 3. That is, the various untreated powder components listed in Table 11 were weighed and stirred in a 75 mL mill and mixer (TML162, manufactured by Tescom Co., Ltd.), and then surface treatment composition A or its comparative composition was added and mixed. Thereafter, surface treatment composition B listed in Table 11 was added and mixed to obtain each powder composition.
  • TML162 mill and mixer
  • the moisture retention capacity of the powder composition was 2.1% or more in the powder treatment compositions of Examples 49 and 50, in which the surface treatment composition A used contained (c) a polyhydric alcohol, while Comparative Example 18, which did not contain (c) a polyhydric alcohol, showed a low value of 0.6% or less. Furthermore, Reference Example 14 had a moisture retention capacity of 0.4%, and Example 13 had a moisture retention capacity of 2.2%, showing that the Examples showed high moisture retention capacities.
  • Example 51 (Formulation Example) A powder eye shadow was prepared as follows using the components shown in Table 12. After mixing component I in Table 12 in a mixer, surface treatment composition A in II was added and further mixed in the mixer. Next, surface treatment composition B in II was added and mixed to perform treatment I. To this, III was added and mixed, and then IV was added as an oil binder and stirred. Separately, the treated pearl pigment obtained by mixing V, followed by adding the surface treatment agent composition A and the surface treatment agent composition B described in VI in that order and mixing for a short time, was mixed with I to IV, and then VII was added. The mixture was compressed in a press to obtain an eye shadow. The resulting eye shadow had excellent color development and adhesion, was resistant to smudging over time, and provided long-lasting makeup. It also had excellent moldability and demonstrated excellent strength even with a small amount of binder. Furthermore, the powder had excellent fluidity during production, making it easy to handle.
  • compositions containing the components shown in Table 13 and water were mixed and dissolved at the concentrations shown in Table 13, and the resulting compositions were used in the following evaluations.
  • the composition was filled into a 20 mL transparent glass bottle, capped, and left to stand at -5°C and 0°C, respectively. After storage for 1 month and 3 months, the solution state in the storage cabinet was visually confirmed. The solution state (uniformity (presence or absence of separation), presence or absence of precipitates or floating matter) was visually judged based on the following criteria. If the solution state was cloudy or non-uniform, below criteria B, under the temperature conditions in the storage cabinet, it was removed from the storage cabinet and evaluated at 25°C.
  • A At the storage temperature, the solution is slightly cloudy overall, but is a fluid and homogeneous aqueous solution.
  • S Even at the storage temperature it is a translucent and homogeneous aqueous solution, with no visible precipitates or floating matter.
  • SS Even at the storage temperature it is a transparent aqueous solution with no visible precipitates or floating matter.
  • compositions were filled into 20 mL transparent glass bottles, capped, and left to stand at 50°C. After storage for 3 months, the bottles were removed from storage and the state of solution was evaluated visually. For compositions that were transparent and showed no precipitate or floating matter, the bottles were left to stand at 25°C for 3 hours or more, after which the transmittance at 430 nm was measured and evaluated based on the following criteria. (Judgment criteria) D. Precipitates or floating matter are observed. C. Precipitates or floating matter are observed, covering the bottom or the liquid surface thinly. B. Precipitates or floating matter are observed scattered on the bottom or the liquid surface. A.
  • the solution is translucent, and no precipitates or floating matter are observed.
  • S. The solution is transparent, with no precipitates or floating matter and a transmittance of 90% or more but less than 94%.
  • SS. The solution is transparent, with no precipitates or floating matter and a transmittance of 94% or more.
  • compositions of Comparative Examples 1' to 3' were inhomogeneously dissolved at low temperatures and could not be used as treatment agents.
  • the composition of Reference Example 4' became cloudy at low temperatures and dissolved homogeneously when returned to 25°C, but was poor in usability in a low-temperature environment.
  • the treatment compositions of the Examples were uniformly dissolved under both low and high temperature conditions, showed little coloration, and had excellent storage stability. Furthermore, no noticeable odor was observed in the compositions before and after storage at 50°C.
  • Example 2' The surface treatment agent of Example 2' was used in the following evaluations.
  • (Preservative Effectiveness Test of Treatment Composition) A preservative effectiveness test was carried out in accordance with the "Preservative Effectiveness Test Method of the 18th Edition of the Japanese Pharmacopoeia (JP18)." 1. Test strains Ec; Escherichia coli NBRC 3972 Pa; Pseudomonas aeruginosa NBRC 13275 Sa; Staphylococcus aureus (Staphylococcus aureus) NBRC 13276 Ca; Candida albicans (Candida) NBRC 1594 Ab; Aspergillus brasiliensis (black aspergillus) NBRC 9455 2.
  • test bacteria solution (1) Bacteria: Ec, Pa, Sa The bacteria were pre-cultured on SCD agar medium at 32.5° C. for 20 hours. The pre-cultured bacteria were scraped with a platinum loop and suspended in sterilized physiological saline to a concentration of approximately 10 8 cells/mL, which was used as a test bacterial solution. (2) Candida: Ca The bacteria were pre-cultured on Sabouraud glucose agar medium at 22.5°C for 48 hours. The pre-cultured bacteria were scraped with a platinum loop and suspended in sterilized physiological saline to a concentration of approximately 10 8 cells/mL, which was used as the test bacteria solution.
  • the powder foundation of Formulation Example 2' spread well during application, and after application, the dryness of the powder was reduced, giving a pleasant moist feel.Furthermore, even after 8 hours of application or after sweating, there was little change in the appearance of the makeup, and it was a powder foundation that was resistant to smudging and had excellent makeup retention.
  • a loose powder was prepared by treating a mixture of the following powders (pigment-grade titanium oxide 5.0%, red iron oxide 0.02%, yellow iron oxide 0.2%, black iron oxide 0.02%, talc 33.8%, mica 30%, lauroyl lysine 15%, silica 15%) with 4.2% of surface treatment composition A of Example 2′ and 0.8% of a 34.8% aqueous calcium chloride solution as surface treatment composition B.
  • the loose powder of Blend Example 3 was excellent in softness and spreadability, and also made wrinkles less noticeable, resulting in an excellent appearance.
  • A The transparent solution maintains its transparency even after high-temperature storage, with a transmittance of 80% or more. No significant changes are observed in the cloudy solution after storage.
  • A The transparent solution maintains its transparency even after high-temperature storage, with a transmittance of 84% or more. No changes are observed in the cloudy solution after storage.
  • Test Example 2 Evaluation of feel and functionality of powder composition (Preparation of treated powder composition-1: mica) 20 g of untreated mica was weighed into a 75 mL mill and mixer (Tescom Co., Ltd., TML162), and 2.9 g of each surface treatment composition A was added and mixed. Then, 0.6 g of a 34.8% calcium chloride aqueous solution was added and mixed as surface treatment composition B to obtain each powder composition.
  • Examples 11" and 12" listed in Table 18 were also treated in the same manner, except that for surface treatment composition B, 0.6 g of a 50% citric acid aqueous solution or 1.8 g of an aqueous solution of 30% zinc PCA and 35% citric acid was used instead of the calcium chloride aqueous solution, to obtain each powder composition. Unless otherwise specified, each powder composition was prepared and stored for at least 4 days.
  • Treated Powder Composition-2 Inorganic Pigment
  • Untreated inorganic pigments (16.7 g of pigment-grade titanium oxide, 0.4 g of red iron oxide, 2.7 g of yellow iron oxide, and 0.2 g of black iron oxide) were weighed into a 75 mL mill and mixer (TML162, manufactured by Tescom Co., Ltd.), and 2.9 g of each surface treatment composition A was added and mixed. Thereafter, 0.6 g of a 34.8% calcium chloride aqueous solution was added and mixed as surface treatment composition B, to obtain each powder composition.
  • the evaluation was carried out by assigning 5 points if the dispersibility of each treated powder composition relative to the dispersibility of the untreated powder was less than 30%, 3 points if it was 30% or more but less than 50%, 2 points if it was 50% or more but less than 70%, 1 point if it was 70% or more but less than 100%, and 0 points if it was equal to or greater than the untreated powder (100%).
  • the total score for the two oils was calculated, and the evaluation was carried out according to the following criteria. (Evaluation criteria) A 8-10 points B 6-7 points C 3-5 points D 2 points or less
  • the surface treatment compositions of the examples remained uniform even after storage at low and high temperatures, demonstrating excellent usability as surface treatment compositions.
  • the powder compositions with mica surface treatment were excellent in moist feel, softness, compatibility with the skin, and adhesion, and also had a glossy and transparent feel compared to the untreated version.
  • a lighter feel was observed when the pH of surface treatment composition A was lower, but when the pH was below 5, the stability as surface treatment composition A was poor.
  • Examples 5" and 10" were moist and had a smoother feel.
  • the treated powder compositions with inorganic pigment mixed compositions showed excellent dispersibility in both non-polar and polar oils.
  • ⁇ Formulation Example 1′′> (Preparation of treated powder composition and evaluation in emulsion formulation) The various untreated powder components shown in Examples 13" to 16" in Table 18 were weighed and stirred in a 75 mL mill and mixer (TML162, manufactured by Tescom Co., Ltd.), and then surface treatment composition A was added and mixed. Thereafter, surface treatment composition B in Table 2 was added and mixed to obtain a powder composition.
  • Phase B 20.5% dimethicone, 5% isopropyl lauroyl sarcosine, 5% ethylhexyl methoxycinnamate, 3.5% trimethylsiloxysilicate, 2% PEG-20 hydrogenated castor oil tristearate, 3% lauroyl lysine, 1% lauryl PEG-9 polydimethylsiloxyethyl dimethicone, 1% PEG-9 polydimethylsiloxyethyl dimethicone, and 1% disteardimonium hectorite), and dispersed for 20 minutes using a disper.
  • Phase B 20.5% dimethicone, 5% isopropyl lauroyl sarcosine, 5% ethylhexyl methoxycinnamate, 3.5% trimethylsiloxysilicate, 2% PEG-20 hydrogenated castor oil tristearate, 3% lauroyl lysine, 1% lauryl PEG-9 poly
  • Phase A 45.4% water, 2% pentylene glycol, 0.5% sodium chloride, and 0.5% phenoxyethanol was slowly added dropwise, and the mixture was emulsified using a homomixer to prepare each emulsion formulation.
  • the emulsified formulations of the examples were superior in terms of freshness during application and moist feeling of the coating film after application.
  • Examples 14'' and 15'' were particularly less sticky and had an excellent moist feeling.
  • Formulation Example 2′′ Powder Foundation A powder mixture (2.0 g of pigment-grade titanium oxide, 0.1 g of red iron oxide, 0.25 g of yellow iron oxide, and 0.04 g of black iron oxide, 5.0 g of mica, 8.0 g of sericite, and 4.6 g of talc) was treated with 2.9 g of the surface treatment composition A of Example 2′′ and 0.79 g of a 34.8% aqueous solution of calcium chloride as the surface treatment composition B, and further mixed with powders (0.5 g of zinc oxide and methicone, 0.75 g of titanium oxide and aluminum stearate, and Amihope (registered trademark) SB-201 (corn starch, lauroyl lysine, crystalline cellulose)).
  • powders 0.5 g of zinc oxide and methicone, 0.75 g of titanium oxide and aluminum stearate, and Amihope (registered trademark) SB-201 (corn starch, lauroyl lysine, crystalline cellulose)
  • the powder foundation obtained from Formulation Example 2'' was confirmed to have improved strength compared to when untreated powder was used. It also had a fine texture and a moist feel with little roughness or powderiness.
  • Example 1'''' Preparation of Composition and Storage Stability Test at Low and High Temperatures The components shown in Examples 1"' to 4"' in Table 19 were mixed and dissolved at the concentrations shown in Table 19 to obtain transparent surface treatment compositions A. The obtained surface treatment compositions A were used in the following evaluations.
  • compositions were filled into 20 mL transparent glass bottles and left to stand at 50°C. After storage for one month, the bottles were removed from storage and the state of dissolution was evaluated visually. Compositions that were transparent after removal from storage were left to stand at 25°C for 3 hours or more, and the transmittance at 430 nm was measured and evaluated based on the following criteria.
  • Judgment criteria D: Obvious precipitation or separation or other inhomogeneous conditions were observed, making the composition inferior as a surface treatment composition.
  • C Slight precipitation or separation was observed.
  • B The transparent solution maintained its transparency even after high-temperature storage, and exhibited a transmittance of 80% or more.
  • A The transparent solution maintained its transparency even after high-temperature storage, and exhibited a transmittance of 84% or more.
  • Test Example 2''' Evaluation of feel and functionality of powder composition (Preparation of treated powder composition-1: mica) 20 g of untreated mica was weighed into a 75 mL mill and mixer (TML162, manufactured by Tescom Co., Ltd.), and then 2.9 g of each surface treatment composition A was added and mixed. 0.6 g of a 34.8% calcium chloride aqueous solution was then added and mixed to obtain each powder composition. Unless otherwise specified, each powder composition was prepared and stored for 4 days or more.
  • Treated Powder Composition-2 Inorganic Pigment
  • Untreated inorganic pigments (16.7 g of pigment-grade titanium oxide, 0.4 g of red iron oxide, 2.7 g of yellow iron oxide, and 0.2 g of black iron oxide) were weighed into a 75 mL mill and mixer (TML162, manufactured by Tescom Co., Ltd.), and 2.9 g of each surface treatment composition A was added and mixed. Thereafter, 0.6 g of a 34.8% calcium chloride aqueous solution was added and mixed as surface treatment composition B, to obtain each powder composition.
  • the evaluation was carried out by assigning 5 points if the dispersibility of each treated powder composition relative to the dispersibility of the untreated powder was less than 30%, 3 points if it was 30% or more but less than 50%, 2 points if it was 50% or more but less than 70%, 1 point if it was 70% or more but less than 100%, and 0 points if it was equal to or greater than the untreated powder (100%).
  • the total score for the two oils was calculated, and the evaluation was carried out according to the following criteria. (Evaluation criteria) A 8-10 points B 6-7 points C 3-5 points D 2 points or less
  • the surface treatment compositions of the Examples remained uniform even after high-temperature storage, demonstrating excellent usability as surface treatment compositions.
  • the powder compositions with surface-treated mica had excellent moist feel, softness, and adhesion.
  • Examples 1'''' and 2'''' exhibited a heavy application feel, while Example 4'''' had a relatively light application feel.
  • the treated powder compositions of inorganic pigments obtained using the surface treatment agent compositions of the Examples exhibited excellent dispersibility in oil. Furthermore, when added to water, it was confirmed that they also had excellent dispersibility in water.
  • Shear adhesion strength (Pa) The shear adhesive strength of the powder in the prepared mixture was measured using a dynamic viscoelasticity measuring device (TA Instruments, Discovery HR 20). The powder rheology accessory from the same company was used as the jig. The measurement was performed according to the JIS standard (Z 8835).
  • Shear adhesion strength (Pa) The shear adhesive strength of the surface treatment composition mixture powders of the Comparative Examples and Examples was measured using a dynamic viscoelasticity measuring device (Discovery HR 20, manufactured by TA Instruments). The tool used was a powder rheology accessory from the same company. The measurement was performed in accordance with JIS [Z885:2016].
  • the resulting eye shadow had excellent color development and spreadability, was resistant to smudging over time, and provided long-lasting makeup. It also had excellent moldability and demonstrated excellent strength even with a small amount of binder. Furthermore, the powder had excellent fluidity during production, making it easy to handle.
  • Example A50 (Formulation Example) According to the formulation in Table 33, a liquid foundation was prepared as follows. Manufacturing method: After mixing I described in Table 33 in a mixer, surface treatment composition A-2 described in II was added and further mixed in a mixer. Next, surface treatment composition B described in II was added and mixed to perform treatment I. Separately, component III was mixed in advance, and the treated I was added and dispersed, then heated to 80°C, and previously mixed component IV was added and further dispersed. Separately mixed component V was added and emulsified, and then component VI was added, and the mixture was cooled to room temperature with stirring to obtain a liquid foundation. The resulting liquid foundation had excellent color development, spreadability, emulsion stability, and long-lasting makeup.
  • Example A51 (Formulation Example) According to the formulation in Table 34, lipsticks were prepared as follows. Manufacturing method: The ingredients listed in Table 34 were prepared as follows. II was added to I, which had been heated and dissolved at 105°C or higher, and the mixture was heated and dissolved at 90°C. After mixing III in a mixer, surface treatment composition A-2 described in IV was added and further mixed in a mixer. Surface treatment composition B in IV was then added and mixed to perform the treatment of III. III treated with IV was added to component (I + II) and heated and mixed at 90°C. V, dispersed using a three-roller roller, was added. VI was added and heated and mixed at 90°C, followed by degassing. (I + II) was filled into a direct-fill container at 90°C, rapidly cooled in a freezer for 35 minutes, and then the top was shaped at room temperature to obtain a lipstick. The resulting lipstick had a smooth feel.
  • Example A52 (Formulation Example) According to the formulation in Table 35, loose powders were prepared as follows. Production method: After mixing component I described in Table 35 in a mixer, surface treatment composition A-2 described in II was added and further mixed in a mixer. Next, surface treatment composition B described in II was added and mixed to perform treatment I. After treating I, component III was added and mixed, and then component IV was added and mixed, and further component V was added and mixed to obtain a loose powder formulation. The resulting loose powder had a smooth feel and excellent spreadability.
  • Example A54 (Formulation Example) (Makeup Base) A makeup base was prepared using the ingredients shown in Table 37 as follows. Manufacturing method: After mixing II described in Table 37 in a mixer, surface treatment composition A-2 described in III was added and further mixed in a mixer. Next, surface treatment composition B described in III was added and mixed to perform treatment II. Separately, I was mixed, and the treated II was added and dispersed. Separately mixed IV was added and emulsified to obtain a makeup base formulation. The obtained makeup base had excellent color development, spreadability, and emulsion stability, and possessed makeup-lasting properties. Furthermore, when observed under a microscope, it was confirmed that a Pickering emulsion had been formed.
  • the resulting eye shadow had excellent color development, a moist feel, and a good adhesion, and it did not smudge over time, providing long-lasting makeup. It also had excellent moldability and showed excellent strength even with a small amount of binder. Furthermore, the powder had excellent fluidity during production, making it easy to handle.
  • Example A78' (Formulation Example) According to the formulation in Table 39, a liquid foundation was prepared as follows. Production method: After mixing I described in Table 39 in a mixer, surface treatment composition A-19' described in II was added and further mixed in a mixer. Next, surface treatment composition B described in II was added and mixed to perform treatment I. Separately, component III was mixed in advance, and the treated I was added and dispersed, followed by heating to 80°C, and pre-mixed component IV was added and further dispersed. Separately mixed component V was added and emulsified, and then component VI was added, followed by cooling to room temperature with stirring to obtain a liquid foundation. The resulting liquid foundation had excellent color development, adhesion, emulsion stability, and long-lasting makeup.
  • Example A79' (Formulation Example) According to the formulation in Table 40, loose powders were prepared as follows. Production method: After mixing I described in Table 40 in a mixer, surface treatment composition A-19' described in II was added and further mixed in a mixer. Next, surface treatment composition B in II was added and mixed to perform treatment I. After III was added to the treated I and mixed, IV was added and mixed, and then V was added and mixed to obtain a loose powder formulation. The resulting loose powder had an excellent moist feel.
  • Example A80' (Formulation Example) (Sunscreen Emulsion) Sunscreens were prepared using the ingredients shown in Table 41 as follows: Manufacturing method: Surface treatment composition A-19' described in III was added to II described in Table 41, and mixed using a mixer. Next, surface treatment composition B described in III was added and mixed to perform treatment II. I was mixed in advance, and the treated II was added, mixed, and dispersed. IV, which had been mixed separately, was further added and emulsified to obtain a sunscreen emulsion formulation. The resulting sunscreen exhibited good adhesion, emulsion stability and SPF.
  • Example A81' (Formulation Example) (Makeup Base) A makeup base was prepared using the ingredients shown in Table 42 as follows. Manufacturing method: After mixing II described in Table 32 in a mixer, surface treatment composition A-19' described in III was added and further mixed in a mixer. Next, surface treatment composition B described in III was added and mixed to perform treatment II. Separately, I was mixed, and the treated II was added and dispersed. Separately mixed IV was added and emulsified to obtain a makeup base formulation. The resulting makeup base had excellent color development, adhesion, emulsion stability, and makeup long-lasting effect. Microscopic observation confirmed that a Pickering emulsion had been formed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

Le but de la présente invention est de fournir un agent de traitement qui peut être appliqué avec une main d'œuvre réduite, qui peut traiter en surface une poudre par un procédé simple sans exiger de dispositif spécial, et qui présente une excellente stabilité au stockage. La présente invention concerne un procédé de traitement de surface d'une poudre, le procédé comprenant (i) une étape de traitement d'une poudre à l'aide d'un liquide de traitement A, et (ii) une étape de traitement de la poudre à l'aide d'un liquide de traitement B. Le liquide de traitement A contient (a) au moins un composé choisi parmi des acides N-acylamino comportant un groupe acyle et présentant une longueur de chaîne carbonée de C8-C22 et des sels de celui-ci, (b) au moins un composé choisi parmi des acides gras présentant une longueur de chaîne carbonée de C8-C22 et des sels de ceux-ci, (c) un alcool polyhydrique et/ou (d) de l'arginine, et (e) de l'eau. La concentration du composé (a) dans le liquide de traitement A est de 5 % en masse ou plus. Lorsque le liquide de traitement A ne contient pas d'arginine, le rapport massique (composé (b)/composé (a)) du composé (b) et du composé (a) dans le liquide de traitement A est de 0,13 ou moins. Lorsque le liquide de traitement A ne contient pas d'alcool polyhydrique, le rapport en masse (composé (b)/composé (a)) du composé (b) et du composé (a) dans le liquide de traitement A est de 0,25 ou moins. Le liquide de traitement B est une solution aqueuse contenant (f) des ions métalliques et les ions métalliques (f) comprennent des ions d'un métal alcalino-terreux ou d'ions de zinc.
PCT/JP2025/012601 2024-03-27 2025-03-27 Procédé de traitement de surface pour poudre, poudre traitée en surface par ledit procédé, agent de traitement pour poudre, poudre traitée en surface par ledit agent de traitement et composition cosmétique Pending WO2025206232A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2024-051635 2024-03-27
JP2024051635 2024-03-27
JP2024094449 2024-06-11
JP2024-094449 2024-06-11

Publications (1)

Publication Number Publication Date
WO2025206232A1 true WO2025206232A1 (fr) 2025-10-02

Family

ID=97218019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/012601 Pending WO2025206232A1 (fr) 2024-03-27 2025-03-27 Procédé de traitement de surface pour poudre, poudre traitée en surface par ledit procédé, agent de traitement pour poudre, poudre traitée en surface par ledit agent de traitement et composition cosmétique

Country Status (1)

Country Link
WO (1) WO2025206232A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5872512A (ja) * 1981-10-26 1983-04-30 Miyoshi Kasei:Kk メ−クアツプ化粧料
JPH045216A (ja) * 1990-04-24 1992-01-09 Kao Corp アシル化アミノ酸多価金属塩からなる顔料及びこれを含有する化粧料
WO2021049483A1 (fr) * 2019-09-13 2021-03-18 味の素株式会社 Procédé de traitement de surface de poudre, composition d'agent de traitement de surface utilisée à cet effet, et poudre traitée en surface

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5872512A (ja) * 1981-10-26 1983-04-30 Miyoshi Kasei:Kk メ−クアツプ化粧料
JPH045216A (ja) * 1990-04-24 1992-01-09 Kao Corp アシル化アミノ酸多価金属塩からなる顔料及びこれを含有する化粧料
WO2021049483A1 (fr) * 2019-09-13 2021-03-18 味の素株式会社 Procédé de traitement de surface de poudre, composition d'agent de traitement de surface utilisée à cet effet, et poudre traitée en surface

Similar Documents

Publication Publication Date Title
JP6960743B2 (ja) 低分子シリコーン代替油剤
EP3178466B1 (fr) Produit cosmétique en forme de poudre solide
JP6857359B2 (ja) 新規糖誘導体ゲル化剤
CN101107214B (zh) 酯化反应生成物和化妆品
JP4573690B2 (ja) 化粧料用油剤又は皮膚外用剤用油剤、並びに化粧料又は皮膚外用剤
JP2024019506A (ja) 化粧料
JP7460962B2 (ja) 被膜形成組成物
US20100297039A1 (en) Oil-In-Water Emulsion Composition And Method For Producing The Same
JP7404651B2 (ja) 水中油型乳化化粧料及びその製造方法
CN105848634B (zh) 皮肤用水包油型乳化化妆品
JP7129768B2 (ja) 表面処理粉体
JP2006001886A (ja) 表面疎水化処理した金属酸化物油分散体
JP2008050271A (ja) メーキャップ化粧料
TWI690541B (zh) 共聚物
EP4005640A1 (fr) Produit cosmétique et méthode de production de produit cosmétique
JP2005089372A (ja) 毛髪化粧料
JP4968889B2 (ja) 皮膚外用組成物
WO2017188279A1 (fr) Composition pour cosmétiques et produit cosmétique comprenant celle-ci
JP2007055925A (ja) 油性基剤及びこれを含有する化粧料及び皮膚外用剤
US20130189331A1 (en) Surface-treated powder and a method of producing it, and cosmetics comprising the surface-treated powder
JP2005002076A (ja) 油性化粧料
JP7195989B2 (ja) エリスリタン誘導体、及びこれを含有する化粧料
JP7544514B2 (ja) イヌリン及び多価アルコールを含有する化粧料又は皮膚外用剤
JP2012241005A (ja) 水系又は水中油型乳化メイクアップ化粧料
JP2011162516A (ja) 親水性物質含有油性化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25775832

Country of ref document: EP

Kind code of ref document: A1